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FANCA MAINTAINS GENOMIC STABILITY THROUGH REGULATING BUBR1 
ACETYLATION 
 
Fanconi Anemia (FA), a chromosomal instability syndrome, is characterized by 
bone marrow failure, genetic malformations, and predisposition to malignancies 
like acute myeloid leukemia (AML) and solid tumors. FA is caused by germline 
bi-allelic mutations in one of 21 known FA pathway genes and somatic mutations 
in FA genes are also found in a variety of sporadic cancers. Recently, numerous 
reports have discovered that the protective function of the FA pathway extends 
beyond its canonical role in regulation of DNA repair in interphase. In particular, 
the FA pathway has been shown to function in essential mitotic processes 
including spindle assembly checkpoint (SAC), cytokinesis, and centrosome 
maintenance.  
 
Understanding of the mechanistic origins of genomic instability leading to 
carcinogenesis and bone marrow failure has important scientific and clinical 
implications. To this end, using a micronucleus assay, we showed that both 
interphase DNA damage and mitotic errors contribute to genomic instability in FA 
ex vivo and in vivo. Functional studies of primary FA patient cells coupled with 
super-resolution microscopy revealed that FANCA is important for centrosome 
v 
dependent spindle assembly supporting the protective role of FA pathway in 
mitotic processes. 
 
Furthermore, we dissected the interactions between the FA pathway and cellular 
kinase networks by employing a synthetic lethality sh-RNA screen targeting all 
human kinases. We mapped kinases that were synthetically lethal upon loss of 
FANCA, particularly those involved in highly conserved signal transduction 
pathways governing proliferation and cell cycle homeostasis. We mechanistically 
show that loss of FANCA, the most abundant FA subtype, results in in premature 
degradation of the mitotic kinase BUBR1 and faster mitotic exit. We further 
demonstrate that FANCA is important for PCAF-dependent acetylation of BUBR1 
to prevent its premature degradation. 
 
Our results deepen our understanding of the molecular functions of the FA 
pathway in mitosis and uncover a mechanistic connection between FANCA and 
SAC phosphosignaling networks. These findings support the notion that further 
weakening the SAC through targeting kinases like BUBR1 in FA-deficient 
cancers may prove to be a rational therapeutic strategy. 
 
Grzegorz Nalepa, M.D., Ph.D., Chair 
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CHAPTER ONE 
INTRODUCTION 
 
Clinical features of Fanconi anemia (FA) 
Fanconi anemia (FA) is an inherited chromosomal instability disorder 
characterized by congenital defects, bone marrow failure, cellular hypersensitivity 
to DNA cross-linkers, and increased risk of malignancies. FA is relatively 
uncommon with an incidence rate of 1 in 360,000 live births and a carrier 
frequency of 1 in 181 in North America. However, the prevalence and carrier 
frequency of this disease varies in different geographical areas. Increased carrier 
frequency is seen in geo-specific populations like Ashkenazi Jews, Afrikaners, 
and Spanish Gypsies (Mamrak, Shimamura, & Howlett, 2016; Philip S 
Rosenberg, Tamary, & Alter, 2011).  
 
Congenital defects are present in most FA patients and they include 
malformations of the upper and lower limbs, fused vertebrae, hypopigmentation, 
microcephaly, short stature, and hypogonadism (Figure 1A and B) (D'Andrea & 
Grompe, 2003; Giampietro et al., 1993; Joenje & Patel, 2001; Young & Alter, 
1994). Fanconi anemia, as the name suggests, also involves hematological 
defects. At birth, blood count is normal but macrocytosis (large erythrocytes) is 
not uncommon. This is typically followed by thrombocytopenia (low platelet 
count), neutropenia, and pancytopenia (low blood cell count) by the second 
2 
decade of life (Young & Alter, 1994). By the age of forty, 98% of FA patients 
would have developed myelodysplastic syndrome (MDS), acute myeloid 
leukemia (AML), or bone marrow failure (BMF). The age of onset of BMF, while 
highly variable, is 7.6 years on average (Shimamura & Alter, 2010). 
 
Diagnosis of FA entails a cytogenetic test of patient lymphocytes to quantify 
chromosome breakage and radial forms after treatment with DNA damaging 
agents like Mitomycin C (MMC) or Di-epoxy butane (DEB). If the lymphocyte 
breakage test is inconclusive, a similar test is done on a different cell type, such 
as skin fibroblasts (Auerbach, 2009). Upon discovery of DEB/MMC-induced 
chromosome breakage, the affected FA gene is identified through FA gene-
sequencing panels. Whole-exome sequencing (WES) may be needed for 
patients with a positive breakage test and no mutations within known FA genes, 
although sequencing may be non-revealing if the disease is caused by deep 
intronic mutations or copy number variation. 
 
Management of FA in patients is improving alongside our understanding of the 
etiology of the disease. FA patients are routinely monitored for cytopenia, BMF 
and leukemic transformation. Some forms of treatments, including androgens, 
corticosteroids, or hematopoietic growth factors, are available to stimulate 
hematopoietic functions in FA patients (D'Andrea, 2010). The best long term 
option is hematopoietic stem cell (HSC) transplantation, which is contingent on 
finding a compatible donor (Gluckman et al., 1995; Gluckman et al., 1989; Green 
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& Kupfer, 2009). HSC is ideally performed before the onset of AML/MDS and 
Fludarabine is used to reduce the incidence of graft failure (MacMillan et al., 
2015; MacMillan & Wagner, 2010).  
 
Genetics of FA  
Early on, it was hypothesized that FA is caused by a single gene defect due to 
relatively uniform phenotype. Genetic heterogeneity in FA was first proposed in 
1976 and later confirmed in 1980 through complementation analysis (Schroeder, 
Tilgen, Kruger, & Vogel, 1976; Zakrzewski & Sperling, 1980). Complementation 
analysis is carried out by fusing different FA cells, which are then checked for the 
ability of the fused cells to correct the FA cellular phenotype. The ability of fused 
cells to complement the cross-linker sensitivity conveys different 
complementation groups. Now, with the help of complementation cloning, protein 
association, and positional cloning and sequencing, we know that FA can be 
caused by bi-allelic mutation in one of 21 different genes (Table 1). Mutations in 
FANCO, FANCS, and FANCR (RAD51) do not result in classical FA phenotype, 
such as bone marrow failure. Thus, these are considered to be FA-like genes. 
Fanconi anemia genes are inherited in an autosomal recessive fashion. FANCR 
(RAD51) and FANCB are exceptions since they are inherited in an autosomal 
dominant and X-linked fashion respectively (Ameziane et al., 2015; Dong et al., 
2015; Meetei et al., 2004).  
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FA and cancer  
As mentioned previously, FA patients have high proclivity towards developing 
malignancies, especially AML. The relative risk of developing AML is increased 
more than 500 folds in FA-patients (Alter et al., 2010; P. S. Rosenberg, Alter, & 
Ebell, 2008). In addition to hematological malignancies, FA patients have 
increased susceptibility to solid tumors like squamous cell carcinoma (SCC) as 
well as adenomas and carcinomas of the liver.  
 
Alter et al. reviewed more than 2000 FA cases (1927-2012) and reported the 
following figures of cancer incidence: Leukemia (188 cases, 8.5%) of which 84% 
were AML, solid tumors (286 cases, 13%) of which 25% were head and neck 
squamous cell carcinoma (HNSCC) and 9.1% were liver carcinomas (Alter & 
Clinician, 2014). In a more geographically restricted study reviewing data of 180 
FA patients from the Italian Fanconi Anemia Registry (1994-2014), Risitano et al. 
reported that FA patients developed a variety of cancers: MDS/AML (13 patients, 
8%) and solid tumors (27 patients, 11%) (Risitano et al., 2016).  
 
Of equal importance, FA genes are frequently mutated in non-FA human cancers 
including breast, ovarian, and pancreatic cancers in non-FA patients (Hahn et al., 
2003; Hwang et al., 2003; Knudson, 1971; Rahman et al., 2007). This includes 
acquired mutations and epigenetic silencing of FA genes (Hess et al., 2008; 
Shen et al., 2015; Xie et al., 2000), including FANCA inactivation in AML (M. 
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Tischkowitz et al., 2003; M. D. Tischkowitz et al., 2004). Analysis of 68 DNA 
sequence datasets reveals that FA genes are mutated in a plethora of human 
cancers in non-FA patients. For example, FA genes are mutated in 4.3% of 
AMLs (188 cases), 36.1% of breast carcinoma (962 cases), and 50.6% of lung 
squamous cell carcinoma (178 cases) among others (Shen et al., 2015). 
Furthermore, somatic BRCA2 (FANCD1) mutations vastly increase the risk of 
developing breast and ovarian cancers (Table 2). An expanded list of FA genes 
and their association to cancer in non-FA patients is found in Table 2. These 
studies may provide a basis for future targeted therapies since loss of FA renders 
cancers susceptible to inhibition of selected signaling pathways that cross-talk 
with FA network. 
 
The Fanconi anemia pathway  
The protein products of the FA genes work together in a common pathway 
termed the Fanconi anemia (FA) pathway. The FA pathway, also known as 
FA/BRCA pathway, functions as a tumor suppressor pathway that guards the 
genome against genomic instability. The most studied role of this pathway is in 
regulating DNA repair of inter-strand crosslinks (ICLs) during interphase. Thus, 
FA-deficient cells are hypersensitive to DNA crosslinking agents like Mitomycin C 
(MMC), Diepoxybutane (DEB), and Cyclophosphamide (Taniguchi & Dandrea, 
2002). The FA pathway is also activated by other DNA damaging agents, such 
as ionizing radiation (IR) and ultraviolet radiation (UV) (Casado, Nunez, Segovia, 
Ruiz de Almodovar, & Bueren, 2005; Dunn, Potter, Rees, & Runger, 2006).  
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During the S-phase of the cell cycle, endogenously or exogenously induced DNA 
cross-links results in replication stall to allow for DNA repair mechanisms, which 
include FA signaling, to operate. First, FANCM recognizes the DNA crosslinks 
through its helicase activity and subsequently recruits the FA core complex. Eight 
FA proteins (FANC -A, -B, -C, -E, -F, -G, -L, -M) and five FA associated proteins 
(FAAP100, FAAP20, FAAP24, HES1, MHF1, and MHF) make up the FA core 
complex (Dong et al., 2015). This complex, through the activity of the E3 ubiquitin 
(ub) ligase, FANCL, and the ubiquitin conjugating enzyme, FANCT (UBE2T), 
monoubiquitinates and activates FANCD2-FANCI heterodimer (also termed ID 
complex). The ID complex then recruits downstream effector proteins, including 
FANCQ (DNA endonuclease), FANCP (scaffolding protein), FANCV (translesion 
synthesis factor), and the recombination proteins FANCD1 (BRCA2), FANCJ, 
FANCN, FANCO, FANCR, FANCS (BRCA1), and FANCU. This results in a 
cascade of events culminating in DNA repair through homologous recombination, 
in which FA proteins are involved (Palovcak, Liu, Yuan, & Zhang, 2017). 
Inactivating the FA pathway is accomplished by deubiquitinating FANCD/FANCI, 
a process regulated by USP1 (ubiquitin-specific peptidase 1) and UAF1 
deubiquitinating complex (Nijman et al. 2005).   
 
In addition to the canonical role in DNA repair, the FA pathway protects against 
another driver of genomic instability, namely oxidative stress. FANCD2 
monoubiquitination and formation of di-sulfide bridges between FANCA and 
7 
FANCG is observed in presence of H2O2, an oxidative agent, reflecting activation 
of the pathway in oxidative conditions (S. J. Park et al., 2004). FA-deficient cells 
also exhibit changes in mitochondrial morphology affecting ATP synthesis and 
detoxification of Reactive oxygen species (ROS) (Kumari, Ya Jun, Huat Bay, & 
Lyakhovich, 2014). ROS can cause alterations to nucleotide bases, like 8-
hydroxyguanine (8-OHG) or 8-oxo-2′-deoxyguanosine (8-oxo-dg). These 
alterations lead to chromosomal instability (CIN) through causing base mismatch, 
insertion, deletions, and chromosomal translocations (Wiseman & Halliwell, 
1996). Importantly FA -deficient cells are hypersensitive to oxidative stress, 
evidenced by elevated 8-OHG, and increased apoptosis (Zunino, Degan, Vigo, & 
Abbondandolo, 2001).  
 
Endogenous sources of oxidative stress, such as aldehydes, are also deleterious 
to DNA and are highly carcinogenic reactive molecules (O'Brien, Siraki, & 
Shangari, 2005). Endogenous aldehydes may be in the form of acetaldehyde 
produced from ethanol metabolism, and crotonaldehyde from lipid peroxidation 
(Voulgaridou, Anestopoulos, Franco, Panayiotidis, & Pappa, 2011). Multiple FA 
patient cells and those derived from Fancd2 null mice are hypersensitive to 
aldehyde accumulation, which supports the implication of FA pathway in 
managing ICLs caused by aldehydes. Interestingly, disruption of aldehyde 
dehydrogenase (Aldh2) promoted perinatal lethality and marrow malfunction 
evolving into lymphoblastic leukemia in Fancd2-/- animals (Garaycoechea et al., 
2012; Langevin, Crossan, Rosado, Arends, & Patel, 2011). 
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FA pathway and mitosis 
The functions of the FA pathway are not exclusive to interphase as mounting 
evidence implicate multiple FA proteins in various mitotic processes. The FA 
pathway ensures faithful chromosome segregation, thus avoiding chromosomal 
instability (Nalepa & Clapp, 2014). 
 
Rosselli et al. reported that the FA pathway monitors unrepaired DNA, namely 
fragile sites, which arise spontaneously or after drug treatment (like APH) (Naim 
& Rosselli, 2009a). Fragile sites are incompletely replicated DNA that persists 
into mitosis causing chromosomal alterations. Interestingly, FANCD2 foci at the 
fragile sites were elevated upon treatment with APH and increased 
micronucleation was observed upon loss of FA signaling. Furthermore, FANCD2 
and FANCI localize to the extremities of ultrafine bridges (UFB), a special class 
of DNA bridges, which connect fragile sites between two sister chromatids 
(Chan, Palmai-Pallag, Ying, & Hickson, 2009; Naim & Rosselli, 2009a). FANCD2 
and FANCI are important in recruiting BLM (Bloom syndrome protein) which 
mediates resolution of UFBs. BLM, a protein that belongs to the RecQ family of 
DNA helicases, is mutated in a rare autosomal recessive disorder termed Bloom 
Syndrome (BS). BS patients share a lot of features with FA patients including 
cancer predisposition, increased incidence of BMF, high CIN levels and 
hypersensitivity to ICL agents (Pichierri, Franchitto, & Rosselli, 2004). Of interest, 
FA-deficient cells exhibited increased chromosomal breakage at the fragile sites 
thus providing a functional link between UFBs and genomic instability (Howlett, 
9 
Taniguchi, Durkin, D'Andrea, & Glover, 2005). These studies argue for a 
functional role of the FA pathway in resolving interphase DNA damage persisting 
into mitosis, protecting the cell against chromosomal instability.  
 
Centrosomes are essential for normal cellular division, and abnormal centrosome 
number is associated with CIN. Supernumerary centrosomes (>2 centrosomes 
per cell) are associated with merotelic kinetochore-microtubule attachment, 
whereby a single kinetochore is attached to the microtubules emanating from two 
poles, resulting in unfaithful chromosome segregation (Ganem, Godinho, & 
Pellman, 2009; Gregan, Polakova, Zhang, Tolic-Norrelykke, & Cimini, 2011). 
Multiple FA proteins localize to the centrosome and are important to maintain 
proper centrosome number (Kim et al., 2013; Nalepa & Clapp, 2014; Zou et al., 
2013). Yet, very few studies functionally connect FA proteins to centrosome 
maintenance. Recently, FANCA was found to be phosphorylated by NEK2 
(never-in-mitosis-gene-a relate kinase 2), a serine/threonine kinase implicated in 
centrosome maintenance, bipolar spindle assembly and proper chromosome 
segregation. This phosphorylation at residue T351 was found to be essential for 
normal centrosome number (Kim et al., 2013). Another study reported that 
another FA protein, FANCJ, functions upstream of and interacts with the mitotic 
regulator, PLK1 (polo like kinase 1), to promote hydroxyurea (HU) and MMC 
induced centrosome amplification in U2-OS cells (Zou et al., 2013). The same 
group showed that both, FANCJ and FANCS (BRCA1), are implicated in PLK1 
dependent centrosome maintenance (Zou et al., 2014). In summary, our 
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understanding of the role of FA in centrosome replication and maintenance is 
advancing but still rudimentary. 
 
During mitosis, the cell employs multiple mechanisms to ensure error-free 
progression of the cytoplasmic and nuclear division. One such mechanism is the 
spindle assembly checkpoint (SAC) which coordinates the events that inhibit 
anaphase onset until proper kinetochore-microtubule attachment are attained 
(Gollin, 2005). Weakened spindle checkpoint increases the risk of random 
chromosome segregation, aneuploidy, and cancer (Musacchio & Salmon, 2007). 
Multiple FA proteins localize to the mitotic spindle and are required for a robust 
SAC, evidenced by multinucleated cells after exposure to taxol, a mitotic poison 
that activates SAC through stabilizing microtubules. Importantly, the 
reintroduction of FA proteins restores mitotic arrest and SAC function (Nalepa et 
al., 2013). Further studies are needed to establish a mechanistic connection 
between the FA pathway and SAC. 
 
FA proteins also participate in cytokinesis, the cytoplasmic division at the end of 
mitosis. Loss of FA signaling results in binucleated cells caused by failed 
cytokinesis. Specifically, FANCD1 (BRCA2) localizes to the central spindle and 
midbody as cells exit cell division. Loss of FANCD1 (BRCA2) resulted in delayed 
cytokinesis and binucleated cells, associated with mislocalization of myosin II, an 
essential protein for cleavage furrow formation (Vinciguerra, Godinho, Parmar, 
Pellman, & D'Andrea, 2010) (X. Wang & Dai, 2006).   
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Fanconi anemia, complementation group A (FANCA) 
FANCA, cloned in 1996, is the most prevalent complementation group in FA. 
Mutations in FANCA account for 65% of all FA cases (Solomon et al., 2015). 
Interestingly, more than 250 different FANCA mutations, including deletions, 
have been identified. Thus, FANCA is a hypermutable gene (Levran et al., 1997; 
Morgan, Tipping, Joenje, & Mathew, 1999). The FANCA gene, harboring 43 
exons, encodes for a 1,455 amino acid long protein. FANCA protein harbors a 
nuclear localization signal (NLS), a partial leucine zipper, and a nuclear export 
signal (NES), which suggests that the protein localizes to the nucleus (Figure 2) 
(Ferrer et al., 2005; Naf, Kupfer, Suliman, Lambert, & D'Andrea, 1998). FANCA 
protein stability is dependent on its interaction with another FA protein, namely 
FANCG (Reuter, Herterich, Bernhard, Hoehn, & Gross, 2000). 
 
The protein interactions of FANCA shed a light on its regulation and molecular 
functions within the cell. FANCA-interacting proteins include Sorting nexin-5 
(SNX5), Brahma-Related Gene 1 (BRG1), IKB Kinase-2 (IKK2) (Reuter et al., 
2000). The functional relevance of these interactions is detailed in Table 3.  
Importantly, FANCA has been shown to have FA core complex-independent 
functions in mitosis. The N-terminus of FANCA directly interacts with the C-
terminus of CENP-E (Centromere-associated protein E). CENP-E acts as a 
motor protein that transports and aligns chromosomes and is thus important for 
proper chromosome segregation (Du, Chen, & Shen, 2009). CENP-E also 
interacts with the mitotic checkpoint complex kinase, BUBR1 (budding 
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uninhibited by benzimidazole-related 1), inducing its autophosphorylation which 
is essential for its SAC activity (Guo, Kim, Ahmad, Zhang, & Mao, 2012). The 
functional relevance of FANCA-CENP-E interaction is yet to be defined.   
 
A Fanca knockout mice model has been generated and homozygote mice 
displayed FA-like features including facial malformations and hypogonadism, 
consistent with high levels of FANCA in testes and ovaries, but failed to replicate 
hematological defects. Homozygote females showed premature oocyte 
senescence, while male homozygotes increased apoptosis in germ cells and 
mis-paired meiotic chromosomes. This study hinted that FANCA may be 
important for reproductive function (Wong et al., 2003). Importantly, FANCA and 
other FA knockout mice fail to fully recapitulate the clinical phenotypes of FA, 
most notably developing anemia (M. Chen et al., 1996).  
 
The spindle assembly checkpoint  
Mitotic division of cells is a highly complex and regulated process. It ensures that 
the duplicated genetic material in S-phase of the cell cycle is distributed evenly 
between two daughter cells. Mitosis is partitioned into six different phases: 
prophase, prometaphase, metaphase, anaphase, telophase, and cytokinesis. In 
prophase, chromosome condensation and polar centrosome migration occur 
followed by microtubule nucleation initiating the formation of the mitotic spindle. 
In prometaphase, the spindle microtubule performs a “seek and capture” to 
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connect to chromosomes through a specialized structure called the kinetochore. 
This is followed by metaphase, in which bipolar attachment of chromosomes 
occurs. Anaphase onset is marked upon loss of sister chromatid cohesion, 
resulting in chromatid separation. In telophase, chromosomes de-condense and 
nuclear envelope reforms, followed by cytokinesis, where cleavage furrow forms 
to split the cytoplasm and form two daughter cells (Imoto, Yoshida, Yagisawa, 
Kuroiwa, & Kuroiwa, 2011).   
 
Proper chromosome segregation is a crucial step towards a successful mitosis. 
This complicated process is governed by a surveillance mechanism provided by 
the spindle assembly checkpoint (SAC), which monitors chromosome alignment 
and orientation as well as kinetochore attachment to the spindle microtubules 
(Naim & Rosselli, 2009b). Chromosome mis-segregation caused by a defective 
SAC could result in changes in oncogene or tumor suppressor gene expression 
leading to genomic instability, a hallmark of cancer (Kops, Foltz, & Cleveland, 
2004).  
 
The complex SAC signaling pathways are mediated by the kinetochore, a 
subcellular structure comprised of at least 80 proteins. The kinetochore is 
composed of two parts, the inner kinetochore, which is the stable structural part, 
and the outer kinetochore that is the site of microtubule binding and SAC activity 
(Cheeseman & Desai, 2008; Santaguida & Musacchio, 2009). Upon mitotic entry, 
unattached kinetochores activate the SAC resulting in recruitment of several SAC 
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proteins, like BUB1. BUB1 (budding uninhibited by benzimidazole 1) is a kinase 
recruited early on in prophase through the KNL1 (Kinetochore Scaffold 1), a 
member of the KMN network (Desai et al., 2003; Jablonski, Chan, Cooke, 
Earnshaw, & Yen, 1998) (Shepperd et al., 2012). BUB1 is essential for 
recruitment downstream SAC effectors, including MAD1 (mitotic arrest deficient 
1) and members of the highly conserved mitotic checkpoint complex (MCC): 
MAD2 (mitotic arrest deficient 2), BUBR1 (budding uninhibited by benzimidazole-
related 1), BUB3 (budding uninhibited by benzimidazole 3), and CDC20 (cell 
division cycle 20). The MCC prevents the activation of the anaphase promoting 
complex/cyclosome (APC/C) thus inhibiting anaphase onset (R.-H. Chen, 
Waters, Salmon, & Murray, 1996). Compared to MAD2 alone, the MCC exhibits 
more than 3000 fold higher inhibitory effect on APC/C (V. Sudakin, Chan, & Yen, 
2001). 
 
The APC/C is a multi-subunit E3 ubiquitin ligase that controls anaphase onset 
(Valery Sudakin et al., 1995). When APC/C is active, the master mitotic regulator 
CDK1 is inactivated and sister chromatid cohesion is lost. Specifically, APC/C 
through its ubiquitin ligase activity targets cyclin B1, the M-phase cyclin that 
binds CDK1, and securin, essential for sister chromatid cohesion, for 
proteasomal degradation signaling entry to anaphase (Hagting et al., 2002).  
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In this work, using a micronucleus assay, we tried to assess the contribution of 
mitotic errors to genomic instability in FA. We then sought to identify the nature of 
these mitotic aberrations (Chapter III). Some of the content in chapter III was 
originally published in Experimental Hematology (2015 Dec 31;43(12):1031-46). 
Furthermore, we used an unbiased shRNA screen to identify perturbed mitotic 
phosphosignaling pathway upon loss of FA. We focused on mechanistically 
understanding how loss of FANCA affects the mitotic functions of essential SAC 
kinases (Chapter IV). We hope that this work contributes to the basic 
understanding of the etiology of FA and lays down the base for future targeted 
therapies in FA-deficient cancers.  
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Figure 1. Fanconi anemia: a complex genetic disorder with developmental 
abnormalities. Thumb and radial abnormalities, vertebral fusion and external ear 
malformation in a FANCC-/- patient (images courtesy of G. Nalepa).  
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FA gene 
name 
Gene synonyms Chromosome 
location 
Protein 
size (aa) 
FANCA FAA, FACA, FANCH 16q24.3 1455 
FANCB FACB, FAAP95 Xp22.31 859 
FANCC FAC, FACC 9q22.3 558 
FANCD1 FAD1, BRCC2, BRCA2 13q12.13 3418 
FANCD2 FA-D2, FA4 3p25.3 1451 
FANCE FACE, FAE 6p21.22 536 
FANCF FAF 11p15 374 
FANCG FAG, XRCC9 9p13 622 
FANCI KIAA1794 15q26.1 1328 
FANCJ BRIP1, BACH1, OF 17q23.2 1249 
FANCL FAAP43, PHF9, POG 2p16.1 380 
FANCM FAAP250, KIAA1596 14q21.3 2048 
FANCN PNCA3 16p12 1186 
FANCO ROVCA3, R51H3, RAD51L2 17q23 376 
FANCP BTBD12, MUS312 16p13.3 1834 
FANCQ RAD1, XPF, ERCC11 16p13.12 916 
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FANCR BRCC5, RECA, RAD51A 15q15.1 340 
FANCS BRCA1, PNCA4, BRCC1 17q21.31 1863 
FANCT UBE2T, HSPC150 1q32.1 197 
FANCU XRCC2 7q36.1 280 
FANCV REV7, MAD2L2 1p36.22 211 
 
Table 1. Summary of known Fanconi anemia genes. Gene name, gene 
synonyms, chromosome locations, and protein sizes encoded by FA genes. The 
table is partially adopted from Table 1 in (Dong et al., 2015) 
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FA gene Association with cancer  citation 
BRCA2 
(FANCD1) 
Mutations result 82% Increased risk of breast 
cancer and 23% increased risk of ovarian 
cancer 
(Hahn et al., 2003; 
Taniguchi et al., 
2003) 
FANCF Hypermethylated promoter is found in 6.7% 
to 30% of testis, lung, ovarian and cervical 
cancer cell lines 
(Marsit et al., 
2004; Narayan et 
al., 2004) 
FANCA Reduced protein levels in sporadic AML (M. D. Tischkowitz 
et al., 2004) 
FANCD2  Reduced protein levels in breast cancer (van der Groep et 
al., 2008) 
FANCL Reduced protein levels in lung cancer cells (J. Zhang, Wang, 
Lin, Couch, & Fei, 
2006) 
FANCO Mutations Increase risk of breast cancer (Goldberg & 
Borgen, 2006) 
FANCC Mutations Increase risk of pancreatic cancer (van der Heijden, 
Yeo, Hruban, & 
Kern, 2003) 
FANCG Mutations Increase risk of pancreatic cancer (van der Heijden et 
al., 2003) 
 
Table 2. Fanconi anemia genes are associated with cancers in non-FA 
patients. Mutations in some FA genes increase the risk of developing different 
types of cancers in non-FA patients. Gene expression of FA genes is decreased 
in some types of cancers or cancer cell lines.  
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Figure 2. Functional domains in FANCA protein. These include a nuclear 
localization signal (NLS) (amino acids 18-29), a partial leucine zipper domain 
(amino acid residues1069-1090), a BRCA1 binding domain, and a CENPE 
binding domain.  
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FANCA interacting 
protein 
Functional relevance of interaction citation 
SNX5 Affects SNX5 trafficking with cell 
surface receptors 
(Otsuki, Kajigaya, 
Ozawa, & Liu, 
1999) 
BRG1 Important for SWI/SNF recruitment 
to target genes 
(Otsuki et al., 
2001) 
CENPE May be important for maintenance of 
mitotic checkpoint signaling 
(Du et al., 2009) 
IKK2  May be important for recruitment of 
IKK2 in response to stress 
(Liu, Otsuki, 
Young, & 
Mercurio, 2000) 
 
Table 3. A list of FANCA interacting proteins. Interaction of FANCA with 
various proteins sheds a light on the cellular functions of this protein. This table 
lists FANCA interacting proteins, the functional relevance of the interaction, and 
the relevant citation. 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
Cell culture 
FANCA-/- primary patient fibroblasts (cell lines: MNHN, RA8851 and JRAST) 
were gifted from Dr. Helmut Hanenberg (Heinrich Heine University, Germany). 
MNHN cells harbor two FANCA mutations: c.3163C>T and c.4124-4125delCA. 
JRAST cells also harbor two FANCA mutations: p.Arg1055Trp and 
p.Thr1131Ala. FANCA-deficient lines have been described and the functional 
gene correction of all cell lines used in this work has been validated in G2/M 
MMC hypersensitivity assays (Figure 3). Patient fibroblasts, HeLa cells, and 
CENPA-GFP expressing Hela cells were cultured in Dulbecco's modified Eagle 
medium (DMEM) containing 10% fetal bovine serum (FBS), 1% penicilin-
streptomycin, 1% sodium pyruvate in 370C 5% CO2 in 5% O2 incubator or normal 
O2 incubators.  
For RO-3306 synchronization, cells at 70% confluency were synchronized by 
adding 10µM RO-3306 and incubated in 370C, 5% CO2 and either 5% O2 or 
normal incubators for 22 hours. Cells were then washed with PBS and released 
into growth media for the noted times. Alternatively, cells were PBS washed after 
RO-3306 synchronization and then released into 10µM MG132-containing growth 
media for 3 hours. Cells were then fixed accordingly for Immunofluorescence or 
protein extracted for IP or WB.  
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For cycloheximide treatment, cells at 80% confluency were treated with 
cycloheximide (CHX) to a final concentration of 20 µg/ml. Cells were treated 
simultaneously for different time points and then collected for western blot using 
protein extraction described below. 
 
shRNA screen 
FANCA deficient patient fibroblasts (FANCA-/-) and their corrected counterparts 
(FANCA+) were plated (2 replicates/cell line) to 50% confluency in 15 cm plates 
(Falcon). The next day (day 1), cells were transduced per manufacturer’s 
protocol with a viral library (MISSION® LentiExpress™ Human Kinases, Sigma 
Aldrich) that contains ∼3200 lenti-viruses carrying sh-RNA sequences that target 
∼501 human kinase genes with a puromycin resistant backbone at a multiplicity 
of infection (MOI) of ~0.5. A non-transduced plate served as a negative control. 
On day 3, cells were selected with 1 µg/ml puromycin media for 5 days. Next, 
cells were pelleted and sent to Sigma for deep sequencing. 
 
Bioinformatics 
The screen shRNA library consists of 4-10 shRNA clones targeting each kinase. 
Four raw copy numbers were determined for each clone representing 2 FANCA+ 
replicates (a and b) and 2 FANCA-/- replicates (c and d). Four ratios were 
calculated from the raw data (a/c, a/d, b/c, and b/d). Kinases with at least one 
shRNA showing a 5-fold copy number fold change (increase or decrease) 
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between FANCA+ and FANCA-/- cells in all four comparisons were considered 
significant. Raw data was also processed using the Panther gene classification 
database to confirm significant results.   
 
shRNA transduction 
To generate stable shRNA-expressing FANCA gene-corrected and uncorrected 
fibroblasts, lentiviral particles were produced and transduced as described previously 
(Staser et al., 2013). Control shRNA, BUB1 (clone ID NM_004336.x-1478s1c1, clone 
ID NM_004336.x-2991s1c1, clone ID NM_004336.3-520s21c1) and BUBR1 (clone 
ID NM_001211.x-3346s1c1, clone ID NM_001211.x-1705s1c1, clone ID NM_001211.x-
1560s1c1). Cells were transduced for 48 hours, selected with 1 µg/ml puromycin for 5 
days, and then used for indicated experiments.  
 
siRNA transfection  
Using siPORT NeoFX transfection reagent (Ambion), cells were reverse-
transfected in 6-well plates (50,000 cells per well) or 10-cm plates (250,000 cells) 
with 25 nM siRNA on day 1, followed by forward-transfection with 25 nM siRNA 
on day 2. Cells were left to grow for 24-48 hours before harvesting for further 
experiments. List of siRNA purchased from Ambion: FANCA siRNA (s164), 
BUB1 siRNA (s2130, s2131, s2132), Negative control #2 (4390847). 
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Immunofluorescence and Microscopy 
Different methods (referred to as a, b, c, d and e) were used to perform 
Immunofluorescence: Cells were grown on ultrafine glass coverslips (Fisher) 
using the following methods: (a) fixed with 4% Paraformaldehyde (PFA) (Electron 
Microscopy Sciences) in PBS for 20 minutes, (b) pre-extracted with 0.2% 
TritonX-100 (Sigma Aldrich) for 30 seconds at room temperature and then fixed 
with 4% PFA for 20 minutes. Coverslips were then permeabilized and blocked 
with 0.2% triton in 5% BSA (Fisher Scientific) in PBS, (c) cells were pre-fixed with 
4% PFA in PHEM buffer solution (50 mM Pipes, 25 mM Hepes, 10 mM EGTA, 
8.5 mM MgSO4, pH 7.0) for 20 seconds, permeabilized with 0.5% TritonX-100 in 
PHEM buffer for 5 minutes, and then fixed in 4% PFA in PHEM for 20 minutes. 
Coverslips were then quenched with 25mM Glycine in PBS for 20 minutes and 
then blocked with 3% BSA in PBS-T (0.1% Tween in PBS) for 30 minutes, (d) 
fixed with 4% PFA for 15 minutes and then soaked in 50mM NH4Cl for 5 minutes, 
(e) pre-extracted with 0.1% triton for 2 minutes at room temperature, fixed with 
4% PFA for 15 minutes, and then permeabilized with 0.5% triton in PBS for 15 
minutes. Coverslips a, b and c were incubated in primary antibodies diluted in 
either 1% BSA in PBS or PBS overnight. Cells were then PBS washed and 
incubated in secondary antibodies diluted (1:2000) in 1% BSA in PBS or PBS for 
1 hour. Coverslips d and e were blocked with 10% normal goat serum (NGS) 
(Sigma Aldrich) in 0.1% tween in PBS (PBST) for 1 hour and incubated overnight 
in primary antibodies diluted in blocking buffer. All coverslips were washed with 
PBS and incubated in secondary antibodies diluted in blocking buffer for 1 hour. 
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All coverslips were incubated in Hoechst-33342 (Life Technologies) diluted in 
PBS (1:10,000) for 10 min and then mounted using SlowFade Antifade (Life 
Technologies) or mounted directly (without Hoechst incubation) using prolong 
diamond antifade with DAPI (Life Technologies) on pre-cleaned glass slides 
(Fisher Scientific).  
 
For deconvolution microscopy, image stacks (z-section distance: 0.2 μm) were 
acquired on a Deltavision PersonalDx microscope (Applied Precision) with a 
CCD camera using 20×, 60×, or 100× lenses and deconvolved using Softworx. 
Super-resolution structured illumination microscopy (SR-SIM) images were 
acquired on a Zeiss ELYRA PS.1 system with a CCD camera and 60×/100× 
lenses, and processed via SIM/channel-alignment algorithms (Zen-2011; Zeiss). 
Line-intensity profiles were quantified using Imaris (Bitplane). z Sections on 
figures were exported using Imaris. 
 
Images of FA patient marrow aspirates, marrow aspirates of patients diagnosed 
with immune-mediated aplastic anemia with negative chromosome breakage test 
results, marrow cytospins, and peripheral smears were obtained on a Zeiss 
Axiolab microscope with Axiocam-105 color camera. 
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Live Imaging 
Cells were plated at 10,000 cells per quadrant in a 35-mm Hi-Q4 (Ibidi) culture 
dish. The next day, time-lapse phase-contrast images (3 z sections, total = 6 μm) 
were acquired every 2 min for a period of 48 hours using a BioStation IM-Q time-
lapse imaging system (Nikon) equipped with a 20× 0.8 NA Plan Fluor objective 
lens. NIS-Elements AR Analysis 4.10.02 or NIS-Elements Viewer 4.20 
microscope imaging software (Nikon) was used for video analysis. Videos were 
exported via Imaris (Bitplane) and Adobe Photoshop. 112 FANCA+ and 81 
FANCA-/- JRAST fibroblasts were analyzed.  
 
Quantification of intensities on CENPA spots 
Image stacks were transferred to Imaris software (version 7.7.1, Bitplane) for 
analysis. Each image was visualized in surpass view and the region of interest 
was segmented based on presence of DNA (blue channel). Next, xy diameter 
(0.3 µm) and ellipsoid size (0.6 µm) of each CENP-A stained kinetochore was 
manually estimated. Spots function was then used to detect CENP-A stained 
kinetochores based on fluorescence quality threshold (manually determined). 
The fluorescence quality threshold was set to exclude weak spots that represent 
background intensity. Background subtraction function in Imaris was enabled to 
exclude background signal. Statistical calculation was then performed on each 
CENP-A stained kinetochore and the mean intensity of the channel representing 
the protein of interest was exported and used in further analysis. A minimum of 
300 kinetochores were used for the quantification. 
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Immunobloting  
Whole cell extracts from HeLA cells or fibroblasts were prepared using M-PER 
Mammalian Protein Extraction Reagent (Thermo Scientific) containing protease 
inhibitor (Roche) and phosphatase inhibitor (Thermo Scientific) on ice for 10 
minutes. Lysates were centrifuged at top-speed in a microcentrifuge for 10 
minutes. Lysate protein concentrations were normalized using a bicinchoninic 
acid (BCA) assay kit (Pierce) followed by denaturation in NuPAGE sample-
reducing agent and NuPAGE LDS sample buffer (Life Technologies) and boiled 
at 95°C for 5 minutes). Proteins were separated by 12.5% sodium 
dodecyl sulphatepolyacrylamide gel electrophoresis (SDS–PAGE) and 
transferred to high-quality nitrocellulose membrane (Life Tech) in a solution of 
20nM Tris, 150 mM glycine and 20% methanol at 250 mV for 2 hours at 4°C. 
After blocking in LiCor PBS blocking buffer (LI-COR Biosciences) for an hour, the 
membranes were incubated with primary antibodies at 1:1000 dilution in LiCor 
PBS blocking buffer overnight at 4°C. Following overnight exposure, the 
membranes were washed three times with 0.1% Tween 20 in PBS (PBS-
T). Fluorescent-dye-conjugated secondary antibodies (LI-COR Biosciences) 
were used for infrared fluorescence-based detection (Odyssey CLX). Protein 
levels were quantified by measuring the relative fluorescence intensity of bands 
(normalized against loading controls (actin, GAPDH, tubulin, vinculin) using 
Image Studio 2.1 software.    
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For detection of FANCA protein expression, CD34+ cells were lysed in M-Per 
buffer (Thermo Scientific) containing phosphatase and protease inhibitors 
(Roche) and protein concentration was determined by BCA (Pierce). 15 µg of 
protein was loaded per well in a 4-12% gradient Bis-Tris gel (Life Tech). 
Membranes were blocked in 5% milk for 1 hour, and then incubated with anti-
FANCA antibody (ab5063, Abcam) overnight diluted 1:2000 in 5% milk. Blots 
were washed with 0.1% Tween 20 in PBS (PBS-T) and incubated with anti-rabbit 
IgG horseradish peroxidase linked secondary antibody diluted in PBS-T and 
0.5% milk. Signal was detected via the enhanced chemiluminescence system 
(Life Tech). 
 
CD34+ CFU assay  
Transduced CD34+ cells were grown in triplicate (2500 cells/35 mm dish) in 
Methocult (H4434) methylcellulose-based medium containing recombinant 
cytokines (Stem Cell) and varying concentrations of MMC. Plates were incubated 
at 37oC, 5% 02 for 11 days. Colonies were then counted, and defined as clusters 
of >50 cells. 
 
Co-Immunoprecipitation (Co-IP) 
Whole HeLa cell extracts were collected and 1000ug protein lysate was 
incubated at 4°C overnight in columns prepared with rabbit anti-FANCA (Abcam) 
and mouse anti-BUB1 (Abcam) using the Pierce co-immunoprecipitation Kit 
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protocol (Thermo Scientific, Rockford, IL, USA).  Each column was eluted per the 
protocol and subjected to immunoblotting analysis.  
Flow cytometry  
To detect functional correction of isogenic-corrected patient fibroblasts, cells 
were treated with 33 nM MMC, and then harvested upon incubation with HyClone 
HyQTase (Fisher) detachment solution for 15 minutes. Cells were pelleted and 
resuspended dropwise in cold 70% ethanol, and stored at -20oC overnight. The 
following day, cells were spun down and resuspended in FxCycle PI/RNase 
Staining Solution (Life Tech) for cell cycle analysis. For quantification of mitotic 
cells, fibroblasts were treated with 1nM MMC or 1nM taxol for 9 days. Cells were 
then removed from tissue culture plates upon incubation with HyClone HyQTase 
(Fisher) detachment solution for 15 minutes at 37oC followed by 4% 
paraformaldehyde/PBS fixation for 10 minutes. Cells were pelleted, resuspended 
in 90% methanol and stored in -20oC overnight. The next day, cells were 
incubated in 0.5% BSA/PBS for 4 minutes, pelleted and stained with an Alexa 
Fluor 488-conjugated phospho-histone H3 antibody (Cell Signaling) diluted 1:50 
in 0.5% BSA/PBS for 1 hour in the dark. The cells were next washed with PBS 
and analyzed on a FacsCalibur flow cytometer (Becton-Dickinson). Flow 
cytometry data analysis was performed using Flow Jo software. 
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Cytokinesis-block micronucleus assays 
Fibroblasts grown on coverslips were treated with cytochalasin-B (2 μg/mL) for 
24 hours, followed by processing/imaging as described above; anti-CENPA 
immunofluorescence visualized endogenous kinetochores. For drug treatments, 
cells were exposed to 1 nmol/L taxol or MMC for 9 days before cytochalasin B for 
24 hours. A micronucleus was defined based on the following criteria: (i) the 
diameter of the micronucleus must be less than half that of the main nucleus, and 
(ii) the nuclear boundary must be identified between the micronucleus and the 
nucleus. The presence of kinetochores was determined based on visualization of 
CENPA+ foci within the stack of z sections spanning the entire micronucleus. 
For CD34+ experiments, primary human CD34+ cells transduced with green 
fluorescent protein (GFP)-tagged lentiviral shRNA constructs were cultured for 5 
days, sorted on a SORPAria FACS system, attached to coverslips via cytospin 
(450 rpm, 7 min), and analyzed in immunofluorescence assays as described 
above. 
 
Mitotic spindle assembly assay 
Culture plates with live fibroblasts on coverslips were removed from the 37°C 
incubator to replace growth medium with prechilled medium and kept at 4°C for 1 
hour. Next, the cold medium was replaced with medium prewarmed to 37°C, and 
cells were returned to 37°C (15 sec) and immediately fixed (4% 
paraformaldehyde/PBS). For staining with anti-pericentrin and anti-α-tubulin, cells 
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were imaged via deconvolution microscopy. Imaris (Bitplane) was used to 
measure length of microtubules in z sections and count centrosome-associated 
microtubules within stacks. 
 
S-phase quantification  
Cells grown on coverslips were treated for 9 days with 1nM MMC or 1nM taxol as 
described above, pulsed with EdU using the Click-iT® EdU Imaging Kit (Life 
Technologies) for 45 minutes, then fixed and stained per the manufacturer’s 
protocol. Nuclei were counterstained with Hoechst 33342. Cells were imaged on 
the Deltavision deconvolution microscope and the fraction of EdU-positive nuclei 
was manually quantified. 
 
Colony Forming Unit- Fibroblast (CFUF) assay and direct cell count assay 
500 corrected and uncorrected patient fibroblasts were plated on 10-cm cell 
culture dishes. After cellular adherence overnight in 37oC 5% CO2 and 5% 
O2 incubator, cells were treated with either PBS, MMC, Taxol, small molecule 
inhibitor or shRNA and returned to the incubator for total of 14 days followed by 
fixation and staining with 0.4% methylene blue/methanol (Fisher Scientific 
Company). Colonies were manually counted and plates were scanned using an 
Epson color scanner.  
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For direct cell counting, 6-well plates were seeded with 1 x 105 cells/well and 
treated with indicated doses of MMC or taxol for 9 days. Cell counts were 
performed using a hemocytometer. 
 
Small molecule inhibitors  
10 mg of MK 8776 (Cat No. S2375, Selleckchem) stock solution was diluted to 
100 mM in dimethyl sulfoxide (DMSO) and further diluted in fibroblast growth 
medium to a final concentration of 30nM. 10 mg of Volasertib (Cat No. 
S2235, Selleckchem) stock solution was diluted to 100 mM in dimethyl sulfoxide 
(DMSO) and further diluted in fibroblast growth medium to a final concentration 
of 10nM. 5 mg of Roscovitine (R7772, Sigma) stock solution was diluted to 50 
mM in dimethyl sulfoxide (DMSO) and further diluted in fibroblast growth medium 
to a final concentration of 10nM.  
 
Bioinformatics analysis of cancer-associated FA mutations  
Somatic cancer-associated mutations of FANCA were identified within the 
COSMIC database (Forbes et al., 2015). Functional impact of mutations was 
examined with Mutation Assessor algorithm; mutations producing a Functional 
Impact Score (FIS) >1.938 were considered potentially disruptive.  
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in vitro Kinase assay 
BUB1 antibody (Abcam) was used to immunoprecipitate BUB1 from FANCA 
patient fibroblasts (FANCA-), their corrected counterparts (FANCA+), or from 
HeLa cells using Pierce™ Crosslink IP Kit (Thermo Scientific). Protein kinase 
assays were performed in 30 µl reactions. Reaction mixture contained 1µg BUB1 
immunoprecipitates, 2µg H2A (New England Biolabs), 30µM cold ATP, 100 nCi 
P32 ATP (PerkinElmer) in kinase buffer (Cell Signaling). The reactions were 
incubated for 30 mins at room temperature. The reactions were then quenched 
with SDS buffer, resolved by SDS-PAGE, and analyzed by autoradiography to 
detect BUB1-dependent in-vitro phosphorylation of Histone 2A. 
 
Antibodies 
The following primary antibodies were used for IF in this study: FANCA 
(ab201458 or ab5063, Abcam), BUB1 (ab54893, Abcam), CENPA (2186s, Cell 
Signaling Technologies; ab13939, Abcam), BUBR1 (ab54894, Abcam), BUBR1-
Ack250 (gift from Dr. Hyunsook Lee), FANCD1 (Op45 or CA1033, millipore), 
AURKB (611082, BD Biosciences), FANCG (sc393382, Santa Cruz), α-tubulin 
(11126, Life Technologies), PCAF (sc8999, Santa Cruz; 3378, Cell Signaling 
Technologies), anti-pericentrin (Abcam, 1:100), mouse anti-centrin 3 (Santa 
Cruz, 1:100), mouse anti-Ț-tubulin (Abcam, 1:100), rabbit anti-CEP170 (Abcam, 
1:100). For immunofluorescence, Alexa 488-, Alexa 594-, and Alexa 647-
conjugated antibodies (Life Technologies) were used for primary antibody 
detection.  
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For immunoblotting, the following primary antibodies were used: rabbit anti-
FANCA (Abcam), rabbit anti-BRCA2/FANCD1 (millipore), mouse anti-BUB1 
(Abcam), mouse anti-BUBR1 (Abcam), rabbit anti-acetylated BubR1 (gift from Dr. 
Hyunsook Lee), rabbit anti-cyclin B1 (Cell Signaling Technology), mouse anti-
cdc27 (BD Biosciences), mouse anti-actin (Sigma-Aldrich), and rabbit anti-
GAPDH (Cell Signaling Technology). 
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Figure 3. Functional rescue of FANCA isogenic gene defect in primary 
patient fibroblasts. Cell cycle flow profiles of FANCA-deficient patient line 
MNHN (top), JRAST (middle), and RA885 (bottom). Primary patient cells and 
their isogenic gene-corrected counterparts were either untreated or treated with 
MMC for 48 hours and analyzed for DNA content via flow cytometry to determine 
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functional FA correction. Note partial correction of MMC-induced G2/M arrest in 
FANCA−/− patient cells on correction with wild-type FANCA.  
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CHAPTER THREE 
INTERPHASE AND MITOTIC ERRORS RESULT IN GENOMIC INSTABILITY IN 
FA 
 
Introduction 
Fanconi anemia (FA/BRCA) pathway is an intricate plexus of at least 21 proteins 
that maintain genomic stability, control growth and development, and prevent 
cancer. Bi-allelic germline disruption of any FA gene causes Fanconi anemia 
(FA), a genetic disorder characterized by developmental abnormalities, bone 
marrow failure (BMF), myelodysplasia and high risk of cancer, particularly acute 
myeloid leukemia (AML) (Alter, 2014; Alter et al., 2010; D'Andrea, 2010; 
Kottemann & Smogorzewska, 2013; P. S. Rosenberg et al., 2008). Heterozygous 
inborn mutations in the BRCA branch of FA network increase risk of breast and 
ovarian cancers as well as other tumors (D'Andrea, 2010; Howlett et al., 2002; 
Jones et al., 2009; Sawyer et al., 2015; Seal et al., 2006), and somatic mutations 
of FA/BRCA genes occur in malignancies in non-Fanconi patients (Narayan et 
al., 2004; Taniguchi et al., 2003; M. Tischkowitz et al., 2003; M. D. Tischkowitz et 
al., 2004). Thus, disruption of FA/BRCA signaling promotes malignancies in the 
inherited genetic syndromes and in the general population. 
The FA/BRCA pathway prevents cancer by protecting genome integrity. In 
interphase, DNA damage response (DDR) initiates the assembly of the multi-
protein FA complex at damage sites to arrest the cell cycle as the cascade of 
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effectors repairs the lesions (D'Andrea, 2010; Kottemann & Smogorzewska, 
2013). These compartmentalized bursts of FA activity handle multiple genotoxic 
insults, from endogenous aldehydes (Garaycoechea et al., 2012; Langevin et al., 
2011) to replication errors and mutagen exposure. Thus, the FA/BRCA network 
provides a crucial line of defense against interphase mutagenesis (D'Andrea, 
2010; Kottemann & Smogorzewska, 2013).  
 
Less is known about the role of the FA/BRCA pathway during mitosis, but FA 
signaling has been recently implicated in the maintenance of normal centrosome 
count (Kim et al., 2013; Nalepa et al., 2013; Zou et al., 2013; Zou et al., 2014), 
spindle assembly checkpoint (SAC) (London & Biggins, 2014; Nalepa et al., 
2013), repair of anaphase bridges (Chan et al., 2009; Naim & Rosselli, 2009a) 
and execution of cytokinesis (Daniels, Wang, Lee, & Venkitaraman, 2004; 
Mondal et al., 2012; Vinciguerra et al., 2010). Since chromosomal instability due 
to mitotic errors is a hallmark of cancer (Gordon, Resio, & Pellman, 2012; 
Hanahan & Weinberg, 2011) and a therapeutic target (Bakhoum & Compton, 
2012), these findings may have translational relevance. However, it is unknown 
whether these ex vivo observations are applicable to in vivo hematopoiesis.  
 
Here, we present quantitative evidence that loss of FA signaling disrupts mitosis 
during in vivo hematopoiesis in humans, and that both aberrant interphase and 
mitotic failure contribute to genomic instability due to FA deficiency. Super-
resolution microscopy revealed that FANCA shuttles to the pericentriolar material 
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at mitotic entry to regulate centrosome-associated spindle nucleation. We found 
that primary FANCA-/- cells escape chemotherapy-induced SAC to replicate 
despite genomic instability. Our cell-survival assays showed that FA-deficient 
cells are hypersensitive to taxol (an antimitotic chemotherapeutic). Sublethal 
taxol doses exacerbated genomic instability in FA-/- cells through mitotic errors 
while low-dose MMC activated the G2/M checkpoint and DNA breakage. 
Therefore, distinct classes of chemotherapeutics inflict unique damage patterns 
in FA-/- cells, which may have implications for future strategies against FA-
deficient cancers. Together, our findings provide insights into complex 
mechanisms of genomic instability in FA.  
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Results 
 
In vivo error-prone mitosis during FA-/- hematopoiesis.  
Mitotic failure was reported in FA cells ex vivo, and cytokinesis failure was 
documented in FA marrows (Nalepa et al., 2013; Vinciguerra et al., 2010). 
However, the in vivo evidence of abnormal early mitosis in hematopoietic cells of 
FA patients has been missing. To examine whether loss of FANCA, the gene 
most commonly disrupted in FA (D'Andrea, 2010), predisposes hematopoietic 
cells to erratic divisions in vivo, we quantified mitotic errors in marrow aspirates 
of two FANCA-/- patients with pancytopenia but no MDS/AML. Consistent with 
the role of FANCA in cell division, we observed increased frequency of abnormal 
mitotic figures in FANCA-/- marrows compared to marrow aspirates of patients 
diagnosed with immune-mediated aplastic anemia after excluding FA by negative 
chromosome breakage tests (Figure 4A, p=0.01). Lack of chromosome 
congression leading to lagging chromosomes in anaphase and micronucleation 
at mitotic exit reflects weakened SAC or merotelic attachment due to centrosome 
malfunction (Nalepa et al., 2013). The DNA bridges in late mitosis may reflect 
impaired resolution of ultrafine anaphase bridges (Naim & Rosselli, 2009a). 
Interphase nuclear morphology in the erythroid lineage provided further evidence 
of in vivo mitotic abnormalities (Figure 4B-C). Erythroblast micronucleation 
(Figure 4B) suggests failure to segregate chromosomes into the daughter nuclei. 
Presence of bizarre erythroblasts with multilobed nuclei (Figure 4B) is consistent 
with impaired chromosome segregation due to erroneous SAC followed by 
42 
cytokinesis failure (Nalepa et al., 2013; Vinciguerra et al., 2010). Binucleated 
erythroblasts (Figure 4B) reflect lack of cytokinesis after normal chromosome 
division (Vinciguerra et al., 2010). These results provide quantitative in vivo 
evidence that abnormal mitoses occur with increased frequency in the 
hematopoietic cells of FANCA-/- patients before development of MDS/AML. 
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Figure 4. Chromosomal instability and abnormal mitoses during 
hematopoiesis in human FANCA-/- patients. (A) Representative abnormal 
mitoses in FANCA-/- patient bone marrow aspirates. Quantification (upper right) 
represents data from 2 different FA patients and 2 non-FA patients (96 mitoses in 
non-FA and 73 mitoses in FA; Fisher’s exact test). Scale bars: 5 µm. (B) 
Examples of abnormal interphase nuclear morphology in FANCA-/- patients’ 
hematopoietic cells that have undergone aberrant mitoses compared to a normal 
non-FA interphase erythroblast. Scale bars: 5 µm (C) Micronucleation of FANCA-
/- bone marrow erythroblasts, reticulocytes and mature red blood cells top. Scale 
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bars: 5 µm (top); 2µm (bottom). All specimens were imaged with Zeiss Axiolab 
system equipped with an Axiocam 105 color camera.  
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A combination of interphase and mitotic errors drives genomic instability 
in FA.  
Since BMF and hematopoietic malignancies are consistent clinical hallmarks of 
FA (D'Andrea, 2010; Kottemann & Smogorzewska, 2013), we quantified the 
contribution of interphase and mitotic abnormalities to genomic instability in 
FANCA-deficient hematopoietic cells. A modified micronucleus assay (Figure 
5A) (Fenech, 2007) allowed to determine the origin of multinucleation in primary 
human CD34+ hematopoietic cells transduced with an shRNA (short hairpin 
RNA) against FANCA (Nalepa et al., 2013) compared to control CD34+ cells. We 
validated the FANCA shRNA in human CD34+ cells (Figure 5B-C). Upon 
FANCA knockdown, CD34+ cells were immunostained for endogenous CENPA 
(a kinetochore marker (Palmer, O'Day, Trong, Charbonneau, & Margolis, 1991)) 
and imaged by deconvolution microscopy to classify cells based on the presence 
of CENPA+ foci. As described (Fenech, 2007), additional kinetochore-positive 
nuclei arise through whole-chromosome missegregation in mitosis, and 
supernumerary kinetochore-negative nuclei result from DNA fragmentation 
(Figure 5A). FANCA-knockdown CD34+ cells developed higher multinucleation 
due to both chromosome breakage (p=0.0083) and faulty chromosome 
segregation (p=0.0001) compared to control CD34+ cells (Figure 5D-E). We 
concluded that silencing FANCA impairs both interphase and mitotic genome 
maintenance in human hematopoietic cells.    
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To validate this finding in primary FA-deficient patient cells and eliminate the 
possibility of non-specific shRNA-induced phenotype (Sigoillot et al., 2012), we 
pursued cytokinesis-block cytome assays (Fenech, 2007). Dividing cells are 
treated with cytochalasin B, a cytokinesis inhibitor, prior to CENPA 
immunofluorescence. Inhibition of cytokinesis generates binucleated cells upon 
error-free chromosome partition, and the presence of micronuclei indicates 
abnormal chromosome segregation during the last mitosis. Again, CENPA-
positivity distinguishes mitotic-failure micronuclei from DNA-breakage micronuclei 
(Figure 6) (Schuler, Rupa, & Eastmond, 1997).  
 
FANCA-/- fibroblasts had increased frequency of both chromosome 
missegregation (p=0.0391) and chromosome breakage (p=0.0218) compared to 
isogenic gene-corrected cells (Figure 7A-B). Thus, disruption of FA signaling 
impairs interphase and mitotic fidelity not only during hematopoiesis (Figure 4), 
but also in fibroblasts (Figure 7). These findings suggest that FANCA, a member 
of the FA/BRCA pathway, may play evolutionarily conserved roles in mitotic 
genome housekeeping.  
  
47 
 
Figure 5. FANCA maintains genomic integrity during interphase and 
mitosis in primary human CD34+ cells. (A) Assay schematic. 
Kinetochore/centrosome immunofluorescence staining distinguishes 
multinucleation generated through whole-chromosome missegregation from 
multinucleation resulting from DNA breakage. (B) FANCA shRNA efficiently 
knocks down FANCA protein in primary human CD34+ cells. -actin serves as 
loading control. (C) Functional validation of FANCA shRNA in primary human 
CD34+ cells. FANCA shRNA renders CD34+ cells hypersensitive to mitomycin C 
compared to CD34+ cells compared with control shRNA. Error bars represent 
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mean +/- SEM and significance was determined using a two-way ANOVA with 
Sidak correction. (D) Representative images of multinucleation resulting from 
FANCA knockdown in human CD34+ cells. Regions of interests are marked in 
red or yellow and enlarged on the right. Green arrow points to a CENPA-positive 
centromere/kinetochore within the supernumerary nucleus. Scale bars: 2µm (left) 
and 1µm (right) (E) Quantification of multinucleation resulting from weakened 
SAC or chromosome breakage in control and FANCA-knockdown CD34+ cells. 
At least 500 cells per group were counted. Results were analyzed using a 
student’s t-test and represented as mean +/- SEM.  
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Figure 6. Schematic representing micronucleus assay. Schematic of the 
cytokinesis-block micronucleus test that delineated the origin of aneuploidy 
based on the presence or absence of kinetochores within micronuclei. 
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Figure 7. Micronucleation upon loss of FA signaling results from a 
combination of interphase and mitotic errors. (A) Representative images of 
micronuclei in FANCA-/- primary patient fibroblasts. Scale bars: 10µm (left) and 
2µm (right) (B) Quantification of micronuclei resulting from whole-chromosome 
missegregation versus chromosome breakage in primary FANCA-/- and FANCA+ 
fibroblasts. Error bars represent mean +/- SEM. At least 260 cells were counted 
per condition and significance was determined by student’s t-test. Cells were 
imaged with deconvolution microscopy (Applied Precision personalDx) and 
deconvolved with Softworx imaging suite (10 iterations, ratio: conservative). 
 
 
  
51 
FANCA shuttles to the pericentriolar material during mitotic centrosome 
maturation.  
Multiple FA proteins, including FANCA (Figure 8F-G), localize to centrosomes 
and mitotic spindles (Kim et al., 2013; Nalepa et al., 2013; Zou et al., 2013). 
However, it is unknown whether FANCA association with centrosomes changes 
between interphase and mitosis, as expected of a bona fide regulator of mitotic 
centrosome/spindle function (Lee & Rhee, 2011; Sdelci et al., 2012).  
 
Centrosome maturation prepares centrosomes for mitosis through reorganization 
of the pericentriolar material (PCM). A phosphosignaling circuit of cyclin-
dependent kinases (CDKs), polo-like kinase 1 (PLK1) and Aurora A (Joukov, 
Walter, & De Nicolo, 2014) recruits pericentrin (Lee & Rhee, 2011) and γ-tubulin 
(Sdelci et al., 2012) to the PCM at mitotic entry to increase the spindle-nucleating 
centrosome activity (Zimmerman, Sillibourne, Rosa, & Doxsey, 2004). Since 
FANCA regulates spindle assembly (Figure 8B-E), we wondered whether 
FANCA is recruited to the PCM of maturing centrosomes similar to these other 
centrosome-spindle regulators. To examine FANCA sub-centrosomal 
localization, we employed deconvolution and super-resolution microscopy, which 
allows visualization of centrosomes beyond the diffraction limit imposed by 
conventional microscopes (Lawo, Hasegan, Gupta, & Pelletier, 2012; Mennella, 
Agard, Huang, & Pelletier, 2014). At mitotic entry, FANCA shuttled from 
centrioles towards the PCM and co-localized with pericentrin, α-tubulin and the 
minus end of spindle microtubules until the mitotic exit (Figure 8A-B, Figure 10-
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11). In interphase, FANCA returned to the mother centriole (Figure 12). These 
observations were confirmed with multiple primary antibodies and imaging of 
FANCA-/- patient cells stably expressing GFP-FANCA. 
 
To thoroughly analyze FANCA distribution within the PCM, we analyzed 
individual 84-nm-thin super-resolution sections of mitotic centrosomes. At the 
mid-centrosome level, we observed well-organized FANCA fibers extending 
through and beyond the pericentrin-decorated PCM network from centrioles 
towards microtubule nucleation sites (Figure 9B-C). This dynamic relocalization 
of FANCA to the PCM during mitosis supports the newly discovered role of 
FANCA in spindle microtubule nucleation (Figure 8).  
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Figure 8. Loss of FANCA disrupts spindle microtubule assembly at 
prometaphase centrosomes. (A) Experiment design. Microtubules of living 
FANCA-/- and FANCA+ cells were destabilized by cold treatment (4oC for 1 
hour). Cells were then returned to 37oC to initiate microtubule reassembly and 
fixed with 4% paraformaldehyde 15 seconds later. (B) Cold treatment fully 
destabilizes microtubules in FANCA+ and FANCA-/- prometaphase cells. (C) 
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Representative images of mitotic spindle assembly in FANCA+ and FANCA-/- 
prometaphase cells stained with anti-α-tubulin (green) and anti-pericentrin (red) 
antibodies. Images were captured with 60x lens on the Deltavision deconvolution 
microscope. Scale bars: 2µm (left and right) and 500nm (region of interest 
showed in the center). (D, E) Quantification of spindle microtubules per 
centrosome (D) and the microtubule length (µM) (E) in gene-corrected and 
FANCA-/- cells treated as described in (A). Data represents 2 independent 
experiments (n=130 microtubules/experiment), and error bars represent SEM. (F) 
Representative mitotic HeLa cell stained with anti-FANCA (red) and anti-α-tubulin 
(green) antibodies, imaged on an ELYRA PS.1 super-resolution microscope 
using SIM technology. Insert shows enlarged centrosome-containing region of 
interest. White line shows the line of fluorescence intensity profile. Scale bar: 
2µm. Cells were imaged with deconvolution microscopy (Applied Precision 
personalDx) and deconvolved with Softworx imaging suite (10 iterations, ratio: 
conservative). (G) Fluorescence intensity profiles of FANCA (red) and α-tubulin 
(green) signal. 
55 
 
Figure 9. FANCA shuttles to the pericentriolar material during mitosis. (A) 
HeLa cells were immunostained with antibodies against endogenous FANCA 
(red) and centrin (green), imaged with deconvolution microscopy (Applied 
Precision personalDx) and deconvolved with Softworx imaging suite (10 
iterations, ratio: conservative). Fluorescence intensity profiles demonstrate that 
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FANCA colocalizes with centrin in interphase and migrates away from centrioles 
at metaphase. Scale bars: 1.5 µm (left) and 300 nm (right) (B) Representative 
super-resolution image of human fibroblast stably expressing GFP-FANCA and 
stained with antibody against the pericentriolar material marker (pericentrin). 
Inserted 3D rendering of the centrosome shows colocalization of GFP-FANCA 
and pericentrin. Scale bars: 2 µm. The yellow region of interest is magnified (C) 
to show FANCA fibers embedded within the PCM (centrosome cross-section) 
and extending towards the spindle (centrosome outer layer section). 
Fluorescence intensity profiles (right) of GFP-FANCA/pericentrin signal at PCM 
and spindle are shown on the right. Scale bar: 500 nm. SR-SIM images were 
acquired on Zeiss ELYRA PS.1 super-resolution microscopy system and 
exported using Imaris imaging suite. 
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Figure 10. Endogenous FANCA colocalizes with pericentrin and γ-tubulin 
during metaphase. Representative super-resolution SIM images showing 
colocalization of endogenous FANCA with pericentrin (A) and γ-tubulin (B) in 
metaphase HeLa cells. While lines indicate location of fluorescence intensity 
profiles (right panels). Scale bars: 2 µm (left) and 500 nm (right) 
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Figure 11. Profile of FANCA and pericentrin localization profile throughout 
the cell cycle. SIM images of HeLa cells stained with antibodies against 
endogenous FANCA (red) and pericentrin (green) during interphase (A), 
prophase (B), metaphase (C) and anaphase (D). Centrosomes were marked with 
yellow squares and enlarged in middle panels. FANCA and pericentrin 
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fluorescence line intensity profiles are depicted for each cell cycle stage. Note 
high overlap of FANCA and pericentrin peaks on mitotic centrosomes (B-D) 
compared to interphase centrosome (A). Scale bars: 3µm (A-D, left) and 500nm 
(A-D, right).  
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Figure 12. FANCA localizes to the mother centriole during interphase. SIM 
images of primary patient FANCA-/-  fibroblasts stably expressing FANCA-GFP 
stained with the antibody against the mother centriole marker CEP170 (red) 
during (A) G1 and (B) S/G2 cell cycle phases. Hoechst 33342 was used to 
counterstain DNA. Areas of interest marked with yellow squares are magnified 
(right panels) to show colocalization of FANCA-GFP and CEP170. Scale bars: 
5µm (left) and 500nm (right).  
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Loss of FANCA allows escape from SAC arrest and apoptosis.  
The FA/BRCA pathway repairs interphase DNA damage (Chandra et al., 2005; 
Heinrich et al., 1998) and participates in the spindle assembly checkpoint (SAC) 
(Nalepa et al., 2013). To examine the fate of FANCA-deficient cells upon SAC 
activation, we employed time-lapse imaging of primary FANCA-/- and gene-
corrected cells treated with taxol, a microtubule-stabilizing chemotherapeutic 
(Figure 13). As described in other cells (Jordan et al., 1996; Woods, Zhu, 
McQueney, Bollag, & Lazarides, 1995), FANCA-corrected, taxol-exposed cells 
entered prolonged prometaphase arrest followed by cell death without exiting 
mitosis. FANCA-/- cells were more likely to escape taxol-induced SAC arrest and 
generate multinucleated interphase-like cells (p=0.0215; Figure 14A-D). These 
findings validate the role of FANCA in the SAC and show that loss of FANCA 
facilitates the escape of chromosomally unstable cells from mitotic death caused 
by unsatisfied SAC (Woods et al., 1995).  
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Figure 13. SAC escape assay schematic. Prolonged activation of SAC triggers 
cell death to prevent genomic instability by eliminating cells that cannot satisfy 
the checkpoint. Escape from SAC followed by erratic chromosome segregation 
and mitotic exit generates multinucleated cells. 
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Figure 14. FANCA-/- cells escape from taxol-induced SAC arrest. (A) 
Representative time-lapse imaging snapshots of FANCA+ and FANCA-/- cells 
exposed to taxol. Note prolonged SAC arrest followed by cell death in gene-
corrected cell and escape for SAC followed by cytokinesis failure and 
multinucleation in FANCA-/- cell. Scale bar: 15 m. Time from mitotic entry is 
shown for each frame. Time-lapse phase-contrast frames of cells grown in 
DMSO supplemented with 10% FBS at 37oC, 5% CO2 were acquired every 2 
minutes for at least 24 hours on a Nikon Biostation live-imaging system (B, C) 
Quantification of time-lapse imaging experiments. FANCA-/- cells are more likely 
to escape SAC and less likely to be eliminated through SAC-associated death 
compared to gene-corrected isogenic cells (p=0.0215). Data for 115 mitotic 
FANCA+ cells and 129 mitotic FANCA-/- cells (three experimental replicates for 
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each cell line) were analyzed with two-tailed t-test. See Supplemental Movies 1-
2. (D) Prolonged prometaphase arrest in FANCA+ cells and multinucleation in 
FANCA-/- cells upon 24-hour exposure to taxol in an independent experiment. 
Images acquired on an Applied Precision personalDx deconvolution microscope.   
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FANCA-/- cells are hypersensitive to taxol.  
A significant fraction of multinucleated cells that escape taxol-induced arrest 
(Torres & Horwitz, 1998) or form upon failed mitosis (Cuomo et al., 2008; Mikule 
et al., 2007) is physiologically eliminated to prevent genomic instability(Crasta et 
al., 2012; Gordon et al., 2012). Complete SAC disruption causes chromosomal 
instability incompatible with cell survival (Dobles, Liberal, Scott, Benezra, & 
Sorger, 2000). Thus, we hypothesized that loss of FANCA may render cells 
hypersensitive to taxol. 
 
Since previous studies evaluating response of FA-/- cells to anti-mitotic 
chemotherapeutics generated conflicting data (Kim et al., 2013; van der Heijden 
et al., 2005), we performed rigorous dose-response experiments to thoroughly 
examine this concept. We found that two separate FANCA-/- primary patient cell 
lines harboring different FANCA mutations are hypersensitive to taxol; stable 
FANCA expression rescued taxol hypersensitivity in both lines in two 
independent cell viability assays (Figure 15A-C, Figures 16-17). As expected 
(D'Andrea, 2010; Kottemann & Smogorzewska, 2013), FANCA-/- cells showed 
decreased survival upon exposure to the crosslinking agent mitomycin C (MMC) 
(Figure 15B-C; Figure 18). These findings, together with previously published 
work (Kim et al., 2013), indicate that loss of FANCA is synthetically lethal with 
exposure to anti-mitotic chemotherapeutics.  
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Figure 15. FANCA-/- primary patient cells harboring different FANCA 
mutations are hypersensitive to taxol and MMC (A) Representative colony-
forming (CFU) assay plates. Primary FANCA-/- fibroblasts and FANCA+ 
fibroblasts (500 cells per 10 cm2 plate) were exposed to taxol for 11 days. Note 
decreased colony formation on FANCA-/- plates exposed to 1 nM of taxol. (B) 
Quantification of the CFU assay shown in (C). FANCA-/- cells are more sensitive 
to 1 nM taxol than FANCA+ cells in the CFU assay. 1 nM MMC was used as 
positive control. (H) Direct cell counts confirm that stable expression of FANCA 
rescues both taxol and MMC hypersensitivity of FANCA-/- patient cells. Two-way 
ANOVA with Sidak correction was used for data comparison. Data show pooled 
results of three separate experiments, expressed as the mean ± SEM in 
triplicates.  
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Figure 16. Taxol dose-response curves of FANCA-/- and isogenic gene-
corrected cells. FANCA-/- cells are more sensitive to taxol than FANCA+ cells in 
CFU assays (A) and in manual cell count assays (B). Two-way ANOVA with 
Sidak correction was used for data analysis. Figure shows pooled results of three 
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separate experiments, expressed as the mean ± SEM in triplicates. *p ≤ .05; **p 
≤ .01; ***p ≤ .001; ***p ≤ .0001; ns: not significant. 
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Figure 17. Validation of taxol hypersensitivity in additional FANCA patient 
fibroblast cell lines. Representative plates (A) and quantification (B) from 
colony-forming unit (CFU) assay in which FANCA+ fibroblasts (patient line 
RA885) were exposed to low-dose taxol for 11 days. Error bars represent mean 
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+/- SEM, and a two-way ANOVA with Sidak correction was used to assess 
statistical significance.   
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Figure 18. Rescue of mitomycin C (MMC) hypersensitivity by FANCA gene 
correction in primary FANCA-/- patient cells. (A) Representative CFU assay 
plates of FANCA-/- or gene-corrected fibroblasts treated with indicated 
concentrations of MMC. (B) Normalized colony forming ability (top) of FANCA+ 
or FANCA-/- fibroblasts treated with indicated concentrations of MMC for 11 
days. (C) Cell count assay (bottom) of FANCA+ and FANCA-/- fibroblasts. 6-well 
plates were seeded with 1 x 105 cells/well and treated with indicated doses of 
MMC for 9 days. Cell counts were manually performed using a hemacytometer. 
Two-way ANOVA with Sidak correction was used for data comparison. 
Quantitation of data is representative of three separate experiments and results 
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are shown as mean ± SEM. *p ≤ .05; **p ≤ .01; ***p ≤ .001; ***p ≤ .0001; ns: not 
significant. 
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Chemotherapy-exposed FANCA-/- cells develop distinct patterns of 
genomic instability due to separate interphase and mitotic checkpoint 
abnormalities.  
Having established the hypersensitivity of FA-/- cells to interphase DNA 
crosslinkers and anti-mitotic agents, we wanted to understand how loss of 
FANCA confers hypersensitivity to these separate classes of chemotherapeutics. 
Thus, we examined cell cycle and patterns of genomic instability in primary 
FANCA-/- and gene-corrected cells at baseline (Figure 19) and upon treatment 
with sublethal doses of MMC and taxol. We selected drug doses that decreased 
growth of FANCA-/- cells compared to isogenic FANCA+ cells without fully 
arresting FANCA-/- cells or inducing cell death evidenced by increased sub-G1 
fraction on flow cytometry (Figure 20A and not shown). 
 
Prolonged treatment with 1 nM MMC reduced growth of FANCA-/- cells due to 
persistent activation of the G2/M checkpoint (p=0.0376) reflected by decreased 
DNA replication (p<0.0001) and decreased G1 fraction (p=0.0029) (Figure 20A-
D). This observation is consistent with the exaggerated MMC-induced G2/M 
arrest of FA cells due to the DDR failure (Chandra et al., 2005; Heinrich et al., 
1998). In further support of this notion, exposure to low-dose MMC increased 
multinucleation due to DNA breakage (p=0.0223) but not chromosome 
missegregation (Figure 20F-H). Sublethal taxol exposure affected FANCA-/- 
cells differently. Prolonged treatment with low-dose taxol (but not MMC) 
significantly decreased the mitotic fraction of FANCA-/- cells compared to gene-
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corrected cells (Figure 20I-J, p<0.0001) consistent with impaired SAC (Figure 
15). Furthermore, low-dose taxol increased multinucleation of FANCA-/- patient 
cells (p=0.002) secondary to mitotic chromosome missegregation (p<0.0001) as 
well as chromosome breakage (p=0.0059) (Figure 20K-M). Interestingly, 
multinucleated cells continued to enter S-phase (Figure 21) (Crasta et al., 2012; 
C. Z. Zhang et al., 2015).  
 
In summary, these results (i) provide evidence that both impaired DDR and error-
prone mitosis contribute to chromosomal instability in FANCA-/- cells in vivo and 
ex vivo, (ii) offer insights into the role of FA pathway in the response to DNA-
crosslinking agents and anti-mitotic chemotherapeutics, and (iii) open potential 
new inroads towards synthetic lethal chemotherapy against FA-deficient cancers.  
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Figure 19. Baseline cell cycle evaluation in FANCA-/- fibroblasts and 
FANCA-corrected isogenic cells. FANCA-/- fibroblasts do not show significant 
differences in G1 or G2/M cell cycle fractions quantified by PI flow cytometry (A), 
S-phase fraction quantified by EdU incorporation via microscopy (B) and 
phospho-H3+ mitotic fraction quantified by flow cytometry (C) compared to 
isogenic gene-corrected cells. Increase in spontaneous micronucleation (D-E) is 
consistent with previous studies (Nalepa et al., 2013). Representative 
deconvolution microscopy images of cells of indicated genotypes are shown; 
scale bar=6 um. To quantify incidence of micronucleation, at least 500 
cells/genotype were imaged via deconvolution microscopy as z-stacks spanning 
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whole cells and results were analyzed with Fisher’s exact test. For flow cytometry 
analysis, data generated in 3 independent experiments were pooled and 
compared with two-tailed t-tests. EdU incorporation counts were compared via 
two-way ANOVA with Sidak’s multiple comparisons test. 
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Figure 20. FANCA-/- cells exposed to genotoxic stressors develop genomic 
instability through a combination of interphase and mitotic checkpoint 
abnormalities. (A) Prolonged activation of the G2/M checkpoint in FANCA-/- 
cells grown in low-dose MMC for 9 days. (B) No difference in mitotic cell fraction 
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between MMC-treated FANCA-/- and FANCA+ cells indicates that the increased 
FANCA-/- G2/M fraction shown in (A) reflects G2 arrest prior to mitotic entry. (C, 
D) DNA replication arrest in FANCA-/- cells exposed to 1 nM MMC is rescued by 
FANCA gene correction. S-phase cells were labeled red by EdU incorporation. 
(E, F, G) Increased multinucleation due to DNA breakage, but not chromosome 
missegregation, in FANCA-/- cells grown in low-dose MMC. (H, I) Flow cytometry 
shows decreased fraction of mitotic cells in FANCA-/- cells exposed to sublethal 
dose of taxol. (J, K) Treatment with taxol increases chromosome segregation 
errors and chromosome breakage in FANCA-/- cells. (L) Compound interphase 
and mitotic origins of genomic instability in FA-deficient cells (see text for 
discussion). Exponential accumulation of DNA damage may result in activation of 
cell cycle arrest/apoptosis (bone marrow failure) or malignant transformation 
(leukemia and solid tumors). All flow cytometry data represent pooled 3 
replicates for each cell line and condition compared with two-tailed t-test. EdU 
incorporation counts were compared via two-way ANOVA with Sidak’s multiple 
comparisons test. 
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Figure 21. Continued DNA replication in multi-nucleated FANCA-/- and 
gene-corrected cells. FANCA-/- fibroblasts and isogenic FANCA-corrected cells 
were treated with 1 nM taxol for 9 days to induce multi-nucleation. Then, DNA 
replication in single-nucleated and multi-nucleated cells was quantified in EdU 
incorporation assays as shown on Figure 7. Multi-nucleated cells continue to 
replicate DNA upon abnormal mitotic exit, which may promote further 
accumulation of DNA damage in interphase-like multinucleated cells(Crasta et 
al., 2012; C. Z. Zhang et al., 2015). The frequency of S-phase entry in 
multinucleated cells is not FANCA-dependent (p=1; Fisher’s exact test; n=551 
FANCA-/- cells and 379 FANCA-corrected cells were analyzed). 
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Discussion 
Disrupted FA/BRCA signaling causes genomic instability and cancer. The 
FA/BRCA tumor suppressor network orchestrates interphase DDR and DNA 
replication (D'Andrea, 2010; Kottemann & Smogorzewska, 2013). Multiple lines 
of evidence implicated FA/BRCA signaling in centrosome maintenance and 
mitotic checkpoints (Kim et al., 2013; Naim & Rosselli, 2009a; Nalepa et al., 
2013; Vinciguerra et al., 2010; Zou et al., 2013; Zou et al., 2014), but the in vivo 
importance of these findings is unknown. We found that both abnormal 
interphase and error-prone mitosis significantly contribute to the in vivo 
hematopoietic genomic instability in FA-/- humans, suggesting a role for the 
FA/BRCA network in genome surveillance throughout the cell cycle (Figure 20).  
 
FANCA-/- patients’ hematopoiesis is afflicted by mitotic errors. Lagging 
chromosomes due to an in vivo SAC impairment (Nalepa et al., 2013) and 
persistent anaphase/telophase bridges (Chan et al., 2009; Naim & Rosselli, 
2009a) occur with increased frequency in FANCA-/- patients (Figure 4).  In 
agreement with the work from the D’Andrea group (Vinciguerra et al., 2010), bi-
nucleated hematopoietic cells (Figure 4) are signs of faulty cytokinesis. The 
onset of FA-associated mitotic abnormalities precedes the MDS/AML (Figure 4), 
suggesting that impaired mitosis may contribute to carcinogenesis in FA. Indeed, 
FISH analysis detected chromosomally unstable clones in 15% of FA patients 
with morphologically normal marrows (Mehta et al., 2010), and gross 
chromosomal instability is a hallmark of MDS/AML in FA (Quentin et al., 2011). 
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More research is needed to quantify the impact of haphazard mitosis on FA-
associated myelodysplasia and cancer. 
 
The irregular mitosis during FA-/- hematopoiesis is a consistent but relatively rare 
event (Figures 4-5). Further, while multinucleated cells with centrosome clusters 
are easily seen in FA-deficient cancer cells (Nalepa et al., 2013), multinucleation 
in FA-/- primary cells is more subtle (Figures 5-7) (Nalepa et al., 2013), perhaps 
because cancers cannot eliminate mis-dividing cells through backup checkpoints. 
Indeed, centrosome abnormalities induce TP53-dependent cell cycle arrest 
(Mikule et al., 2007) and apoptosis (Cuomo et al., 2008), and activation of TP53 
contributes to BMF in FA (Ceccaldi et al., 2012). TP53 inactivation boosts 
hematopoiesis but promotes MDS/AML in FA (Ceccaldi et al., 2011), and AML 
with bizarre karyotype instability occurred in an FA patient with somatic loss of 
heterozygosity of the TP53-harboring region of chromosome 17 (Woo et al., 
2011). Thus, aneuploidy and centrosome disruption upon inactivation of the 
FA/BRCA signaling may trigger TP53-dependent checkpoints to limit the risk of 
leukemia at the cost of BMF. 
 
The role of FANCA in mitosis is not clearly defined. Impaired FA signaling 
promotes accumulation of centrosomes due to DDR-induced centrosome over-
replication (Zou et al., 2013; Zou et al., 2014) and deregulated mitosis (Nalepa et 
al., 2013; Vinciguerra et al., 2010). Supernumerary centrosomes promote 
chromosomal instability through multiple mechanisms (Ganem et al., 2009; 
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Gordon et al., 2012). We found that FANCA regulates centrosome-associated 
spindle assembly (Figure 8), and FANCA shuttles from centrioles to the PCM 
spindle attachment sites at mitotic entry (Figures 8-9). Dissecting FANCA-
dependent mitotic centrosome-microtubule-kinetochore interactions in more 
detail will help understand how FANCA regulates the SAC (Nalepa et al., 2013). 
We hypothesize that functional and numerical centrosome abnormalities in FA-
deficient cells may further promote chromosomal instability by promoting 
merotelic kinetochore attachment to spindle microtubules; this mechanism of 
genomic instability has been elucidated in non-FA cells acquiring supernumerary 
centrosomes (Ganem et al., 2009; Nam, Naylor, & van Deursen, 2015). 
Interestingly, as mentioned in the introduction of the thesis, FANCA is 
phosphorylated by the NIMA-related kinase 2 (NEK2) (Kim et al., 2013) and AKT 
kinase (Otsuki et al., 2002); FANCJ and FANCD1 may regulate polo-like kinase 1 
(PLK1) (Zou et al., 2013; Zou et al., 2014), which is essential for spindle function 
(Sumara et al., 2004); and FANCC binds the key mitotic cyclin-dependent kinase 
1 (CDK1) (Kupfer et al., 1997), which co-immunoprecipitates with the FA core 
complex (Thomashevski et al., 2004). Moreover, loss of FANCA is synthetic 
lethal with PLK1 knockdown (Kennedy et al., 2007) and CDK inhibitors disrupt 
IR-induced formation of FANCD2 foci (Jacquemont, Simon, D'Andrea, & 
Taniguchi, 2012). Future work will examine these pathway connections to 
evaluate their translational relevance in cancer and FA.  
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We found that loss of FA signaling is synthetically lethal with taxol exposure, 
highlighting the role of FA-dependent SAC in cell survival. Kim et al observed 
hypersensitivity of FANCA-knockdown cells to nocodazole (Kim et al., 2013). 
Taxol and nocodazole are mechanistically different (Maresca & Salmon, 2010): 
nocodazole disrupts spindle-kinetochore attachment, while taxol renders the 
attached microtubules unable to stretch the kinetochores. Since the FA pathway 
is essential for taxol- and nocodazole-induced SAC (Nalepa et al., 2013), FANCA 
may regulate SAC by intra-kinetochore tension.  
 
Of note, others have found that FANCG/FANCC-deficient pancreatic cancer cells 
exposed to taxol accumulate DNA at similar rate as gene-corrected cells in in 
vitro fluorescence assays (van der Heijden et al., 2005), and concluded that FA-/- 
cells are not hypersensitive to antimitotics. However, FA-/- cells multinucleate 
(Figure 14) (Kim et al., 2013; Nalepa et al., 2013) and replicate (Figure 21) upon 
exposure to antimitotics, suggesting why cell growth assays quantify taxol 
response with better specificity than total DNA measurements. Interestingly, low-
dose taxol promotes chromosome missegregation and DNA breaks in FANCA-/- 
cells. Consistent with this notion, the Pellman group demonstrated that 
micronuclei produced by mitotic errors undergo excessive mutagenesis (Crasta 
et al., 2012) with secondary chromosome breakage (C. Z. Zhang et al., 2015) 
due to erratic replication. The micronucleus-associated chromosome breakage 
may be further exacerbated by failed DDR in FANCA-/- micronuclei.  
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Micronucleation has been noted in FA for decades (Barton et al., 1987; 
Willingale-Theune et al., 1989), but it was unclear whether it reflects interphase 
abnormalities or erratic mitoses. We addressed this question with quantitative 
high-resolution-imaging-based micronucleation assays validated in previous 
studies (Fenech, 2007). Given the key role of FA signaling in interphase 
(D'Andrea, 2010; Kottemann & Smogorzewska, 2013), we addressed whether 
kinetochore-containing micronuclei are not simply a product of impaired DDR. 
Importantly, DNA-crosslinking agent (MMC) produced “DNA breakage” 
micronuclei but not “chromosome missegregation” micronuclei (Figure 20F-G), 
confirming the assay specificity and sensitivity in distinguishing interphase from 
mitotic errors. Thus, we conclude that genomic instability results from DNA 
breakage and chromosome missegregation in multiple FA-/- hematopoietic and 
non-hematopoietic cell types (Figures 4-5). Based on these and other findings 
(Nalepa et al., 2013), we propose that FANCA deficiency causes genomic 
instability through a dual mechanism of impaired interphase DDR/replication and 
defective mitosis (Nalepa & Clapp, 2014) (Figure 20L). This model explains the 
FA-associated patterns of genetic instability and hypersensitivity to both DNA-
crosslinkers and antimitotics. Interphase errors exacerbate mitotic abnormalities 
and mitotic failure promotes interphase mutagenesis. Chromatid remnants 
generated through impaired DDR or replication are randomly segregated in 
mitosis. Defective midbody constriction (Mondal et al., 2012) and cytokinesis 
(Vinciguerra et al., 2010) may shatter lagging chromosomes resulting from 
impaired SAC(Choi et al., 2012; Nalepa et al., 2013) and break unresolved 
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anaphase bridges(Chan et al., 2009; Naim & Rosselli, 2009a). After mitotic exit, 
cells may attempt to repair splintered DNA through chromothripsis, the 
mutagenic process of randomly reconnecting chromosome fragments via non-
homologous end joining (NHEJ) (Forment, Kaidi, & Jackson, 2012; Maher & 
Wilson, 2012; C. Z. Zhang, Leibowitz, & Pellman, 2013). Since FA-/- cells favor 
error-prone NHEJ over homologous recombination (Adamo et al., 2010), 
chromothripsis may have a particularly detrimental impact on genomic stability 
upon loss of the FA/BRCA network.  
 
Our observations unveil the translational importance of mitotic defects caused by 
loss of FA/BRCA signaling. Somatic disruption of FA/BRCA genes occurs in 
malignancies in non-FA patients, including leukemia (Hess et al., 2008; M. 
Tischkowitz et al., 2003; M. D. Tischkowitz et al., 2004; Xie et al., 2000), cervical 
(Narayan et al., 2004), ovarian (Olopade & Wei, 2003; Taniguchi et al., 2003; Z. 
Wang, Li, Lu, Zhang, & Wang, 2006), breast (Wei et al., 2008), bladder (Neveling 
et al., 2007) and lung cancers (Marsit et al., 2004). Our analysis of the COSMIC 
(Forbes et al., 2015) database revealed multiple cancer-associated FANCA-
inactivating mutations in non-FA patients (Figure 22). Since FA-/- cells are 
hypersensitive to antimitotics, future preclinical studies will determine whether 
targeting mitosis can be employed in FA-deficient cancers. This strategy may 
complement other evidence-driven precision medicine efforts against FA-/- 
cancers, such as targeting PARP-dependent DNA repair pathways (Bryant et al., 
2005; Ceccaldi et al., 2015; Farmer et al., 2005), DNA damage kinases (C. C. 
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Chen, Kennedy, Sidi, Look, & D'Andrea, 2009) and selective use of crosslinkers 
(Jacquemont et al., 2012; Taniguchi et al., 2003). 
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Figure 22. Somatic mutations of FANCA in human malignancies. Tumor 
samples harboring amino acid alterations resulting from confirmed missense 
(black circle), nonsense (black square), and frameshift gene mutations (black 
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triangle) in coding regions of FANCA are shown. Mutations that are predicted to 
adversely affect protein function are formatted in bold red, while mutations 
unlikely to affect protein function are shown in black. Cancers associated with 
indicated gene mutations are shown on the left. Protein binding and 
phosphorylation sites of FANCA are shown at the bottom. SCC: squamous cell 
carcinoma; *= nonsense mutation; fs*4=frame shift that causes a translation stop 
four amino acids after the insertion. 
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CHAPTER FOUR 
FANCA MAINTAINS THE SAC THROUGH REGULATING BUBR1 
ACETYLATION 
 
Introduction 
Fanconi Anemia (FA) is a genetic syndrome, characterized by progressive bone 
marrow failure and cancer predisposition, caused by bi-allelic mutations in one of 
21 FA genes. Acquired somatic mutations in FA genes, such as FANCA, have 
been shown to result in AML and solid tumors in the general population (Nalepa 
G., Nature Reviews, 2017). FA pathway is well known for its role in orchestrating 
the DNA damage response (DDR) during interphase (D'Andrea, 2010; 
Kottemann & Smogorzewska, 2013). Recent work suggests perturbed mitotic 
processes, including spindle assembly checkpoint (SAC), to result in genomic 
instability upon loss of FA signaling (Nalepa et al., 2013; Vinciguerra et al., 
2010). The SAC, a phosphosignaling network which includes tumor suppressor 
genes budding uninhibited by benzimidazoles 1 (BUB1) and budding uninhibited 
by benzimidazoles 1 Beta (BUBR1), ensures proper chromosomal segregation 
during mitosis. However, the mechanistic understanding for the cooperation 
between the SAC and FA signaling pathways remains unknown. Our data 
reveals that FANCA-deficient cells depend on SAC proteins, BUB1 and BUBR1, 
for their survival. More importantly, we showcase the BUBR1 signaling axis to 
serve as the common denominator between the SAC kinase network and the FA 
pathway. Our results not only suggest FANCA to play an important role in 
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regulating SAC proteins but also establish the dynamic role of FANCA during 
mitosis. 
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Results 
 
Loss of FANCA is synthetic lethal with knockdown of mitotic SAC protein 
kinases 
We have previously reported weakened SAC upon loss of FA signaling (Figure 
23 A-B, Figure 24, Figure 14, (Nalepa et al., 2013)). The strength of SAC can 
also be assessed through live imaging (Figure 25). Here, we observed 
significantly decreased nuclear envelope breakdown to anaphase onset time in 
FANCA deficient primary patient fibroblasts (FANCA-/-) compared to FANCA-
corrected primary patient fibroblasts (FANCA+) (Figure 25B). This faster mitotic 
exit is supported by decreased levels of mitotic markers, such as CCNB1 and 
Cdc20 in mitotically enriched FANCA-/- cells (Figure 24A and B). However, the 
molecular underpinnings between the FA pathway and SAC remain unknown. To 
interrogate the relationship between FA and SAC pathways in an unbiased 
fashion, we employed a kinome-wide synthetic lethality shRNA screen. FANCA-/- 
and FANCA+ were transduced with a kinome viral library containing 5000 
shRNAs targeting 512 protein kinases (Figure 26). Kinases targeted with at least 
one shRNA with a 5-fold copy number change between FANCA+ and FANCA-/- 
cells were deemed significant (Figure 26). Bioinformatics program was used to 
categorize the significant kinases into relevant cellular pathways (Figure 27) that 
are depicted as a schematic showcasing the signaling networks that may be 
dysregulated in FANCA-/- cells (Figure 28). FANCA-/- cells were hypersensitive 
to silencing of DDR genes, such as ATR, CHK1 and CDK12, which serves as 
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internal validation for our experimental approach. FANCA-/- cells were also 
hypersensitive to loss of kinases implicated in stress response, growth factor 
signaling, and cell cycle. Importantly, the screen identified genes implicated in 
mitotic processes, such as SAC, chromosome segregation and centrosome 
maintenance, to be essential for survival of FANCA-/- fibroblasts (Figure 27).  
 
To confirm our findings and the validity of our screen, we tested whether clinically 
approved small molecule inhibitors, which target kinases that meet significance 
criteria from the screen, would selectively affect FANCA-/- cell survival compared 
to their gene-corrected counterparts. Indeed, colony forming unit-fibroblast 
(CFUF) assay (Figure 29A) revealed that FANCA-/- cells were hypersensitive to 
MK8776 (CHK1 inhibitor), Volasertib (PLK1 inhibitor) and Roscovitine (pan-CDK 
inhibitor) (Figure 29B). Next, we used screen-independent shRNAs targeting 
SAC kinases, BUB1 and BUBR1 (Figure 30A-C). Indeed, decreased CFUF 
formation was noted in FANCA-/- cells compared to FANCA+ cells upon loss of 
BUB1 and BUBR1 (Figure 30B-D). We show that silencing cell cycle-specific 
kinases results in selective death of FANCA-/- cells. 
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Figure 23. Loss of FANCA results in escape from SAC.  Decreased fraction of 
mitotic cells are noted in FANCA-/- MNHN (A) and JRAST (B) fibroblasts 
exposed to 100 nM taxol compared to FANCA-corrected JRAST and MNHN 
fibroblasts via flow cytometry. No difference was observed in untreated 
fibroblasts. Flow cytometry data represents three replicates for each cell line and 
condition, which were analyzed with two-tailed student’s t test.  
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Figure 24. Decreased CDC20 and CCNB1 levels upon loss of FANCA. (A) 
Expression of CDC20 and CCNB1 proteins in FANCA-/- MNHN fibroblasts is 
decreased following 30-minute release from RO-3306 G2 arrest when compared 
to FANCA+ counterparts. No significant difference is observed in CDC20 and 
CCBN1 levels in RO-3306 G2 arrested cells. (B) Western blot showing decreased 
CDC20 and CCNB1 protein levels in FANCA-/- RA8851 fibroblasts compared to 
FANCA+ cells released from RO-3306-mediated G2 arrest. 
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Figure 25. FANCA-/- cells exit mitosis faster compared to FANCA+ cells. (A) 
Representative time-lapse imaging between nuclear envelope breakdown (NEB) 
and anaphase onset in FANCA+ and FANCA-/- fibroblasts. (B) Decreased NEB 
to anaphase onset in FANCA-/- fibroblasts compared to FANCA+ JRAST 
fibroblasts. **P < 0.005, two-tailed student’s t-test was used to quantify 112 
FANCA+ and 81 FANCA-/- JRAST fibroblasts. 
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Figure 26. Design of Kinome-wide screen using shRNAs. FANCA-/- and 
FANCA+ MNHN primary patient fibroblasts (2 replicates) were transduced in 
parallel with pooled lentiviral shRNA kinase library containing 5000 shRNAs 
targeting 512 human kinases. The cells were selected with puromycin, grown 
exponentially for 2 weeks, pelleted, flash-frozen and subjected to high-throughput 
sequencing to quantify individual clones within each biological replicate 
(sequencing depth: 1000x). 
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Figure 27. Kinome-wide shRNA screen hits heat map. A gene map was 
constructed into cellular pathways based on protein kinases with at least a 5-fold 
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copy number difference between FANCA-/- and FANCA+ clones in all four ratios 
(described in methods). 
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Figure 28. Genes in mitotic pathways that are essential for survival of 
FANCA-/- primary patient fibroblasts. Functional genomics provide a cellular 
blueprint of signaling pathways deemed necessary for survival of FANCA-/- cells. 
Loss of FANCA confers cellular lethality upon silencing of genes involved in DNA 
damage response, spindle assembly checkpoint (SAC) and chromosomal 
segregation.  
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Figure 29. FANCA-/- fibroblasts are hypersensitive to inhibition of kinases 
involved in DNA damage and cell cycle pathways using clinical grade small 
molecule inhibitors. Left: Representative scans of colony-forming unit (CFU) 
assay plates of FANCA gene corrected and FANCA-/- patient MNHN fibroblasts 
grown in the presence of indicated inhibitors for 14 days. Right: Quantification of 
colony assays confirms that FANCA-/- cell survival depends on the activity of 
CHK1 (MK8776), PLK1 (volasertib) and CDKs (volasertib). *P < 0.05, ****P < 
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0.0001, ns= non-significant, two-sided student’s t-test. All experiments were 
performed in triplicates.  
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Figure 30. shRNA-mediated silencing of SAC protein kinases, BUB1 and 
BUBR1, confers lethality of FANCA-/- MNHN fibroblasts. (A) BUB1 
knockdown is synthetically lethal with loss of FANCA. Western blot showing 
decreased BUB1 protein expression in FANCA+ and FANCA-/- MNHN patient 
fibroblasts transduced with BUB1 shRNA when compared to control shRNA. (B) 
One representative of two independent BUB1 shRNAs, not included in the kinase 
library, demonstrated decreased colony formation in FANCA-/- fibroblasts in 
comparison to FANCA-corrected fibroblasts and confirmed by quantification of 
the colony assay. (C) BUBR1 knockdown confirmed by western blot, which 
shows decreased BUBR1 protein expression in FANCA+ (left) and FANCA-/- 
(right) fibroblasts transduced with 2 screen independent BUBR1 shRNAs (#1 and 
#2) in comparison to control shRNA. (D) BUBR1 knockdown is synthetically 
lethal in FANCA-/- fibroblasts. Two independent BUBR1 shRNAs, not included in 
the screen, confirm the dependency of FANCA -/- cells on BUBR1 function using 
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CFUF assay. LacZ-targeting shRNA was used as negative control in all 
experiments. *P < 0.05, ****P < 0.0001, ns= non-significant, two-tailed student’s 
t-test. All experiments were performed in triplicates. 
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FANCA localizes to the mitotic kinetochore, when SAC is active 
FANCA, among other FA proteins, localizes to the mitotic spindle and is 
important for a robust SAC (Nalepa et al., 2013). Therefore, we focused our 
attention on synthetically lethal kinases regulating mitosis, specifically the SAC 
tumor suppressor genes BUB1 and BUBR1. BUB1 (budding uninhibited by 
benzimidazole 1) is a protein kinase essential for the SAC and chromosome 
alignment (Perera et al., 2007). BUB1 phosphorylates and inactivates CDC20, 
the anaphase promoting complex (APC/C) subunit that arrests anaphase until 
the SAC is satisfied (Tang, Shu, Oncel, Chen, & Yu, 2004). Further, BUB1 
phosphorylates histone 2A (H2A) to maintain chromosomal stability by recruiting 
shugoshin (Kawashima, Yamagishi, Honda, Ishiguro, & Watanabe, 2010; Tang et 
al., 2004), Aurora B and other SAC components to kinetochores. BUB1 functions 
upstream in the SAC pathway and recruits other SAC proteins, including the 
BUBR1 (BUB1-related) kinase as well as MAD2 (Johnson, Scott, Holt, Hussein, 
& Taylor, 2004; Vigneron et al., 2004). We report that FANCA co-localizes with 
BUB1 at CENPA-associated kinetochores in HeLA cells during prometaphase 
(Figure 31A, 32), which is biochemically evident by the physical interaction 
between FANCA and BUB1 (Figure 31B). Next, we wondered if the biochemical 
interaction between FANCA and BUB1 is functionally relevant. BUB1 
phosphorylates Cdc20 at S156 residue, preventing premature anaphase onset, 
and H2A, ensuring proper chromosome condensation (Kawashima et al., 2010; 
Tang et al., 2004). We show unchanged protein expression of phospho-
Cdc20S156 in FANCA-/- cells compared to their corrected counterparts (Figure 
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33A). In addition, BUB1 kinase activity towards substrates, H1 and H2A, was 
unchanged in cells transfected with FANCA siRNA when compared to control 
siRNA transfected HeLa cells (Figure 33B and C). Further, phosphorylation of 
H2A and its localization to kinetochores was unaffected in FANCA-/- fibroblasts 
(Figure 33D and E). Collectively, BUB1 activity was not affected upon loss of 
FANCA. 
 
We next addressed whether FANCA is recruited to the kinetochore when the 
SAC is activated. Indeed, FANCA localization to kinetochores is the highest 
during prometaphase (Figure 34), with a gradual decrease in kinetochore 
localization as cells exit mitosis. This finding was corroborated by the expression 
of FANCA protein in cells released from G2 arrest (Figure 35A and B). SAC is 
activated either by lack of kinetochore-microtubule attachment or by lack of 
tension at the kinetochores (Li & Nicklas, 1995; Rieder, Cole, Khodjakov, & 
Sluder, 1995). To gain insight into how FANCA behaves in the context of an 
activated SAC, we used two microtubule-modulating drugs: nocodazole, which 
produces tensionless kinetochores in the absence of microtubules and taxol, 
which results in tensionless kinetochores in the presence of microtubules (Figure 
36). We show that FANCA kinetochore localization pattern is distinct in taxol 
versus nocodazole treated cells. When microtubules are stabilized upon 
treatment of taxol, FANCA:BUB1 co-localization (Figure 37, 38A and B) and 
interaction (Figure 40) and co-localization is maximized. Interestingly, when 
treated with nocodazole, FANCA was found to co-localize with Aurora B kinase 
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at the inter-centromeric region (Figure 38-39). These data suggest that FANCA 
localizes to kinetochores upon activation of SAC during prometaphase and 
interacts with SAC proteins, like BUB1, in a microtubule dependent manner.   
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Figure 31. FANCA localizes to the kinetochore and interacts with SAC 
protein kinase, BUB1. (A) Endogenous FANCA co-localizes with endogenous 
BUB1 on CENPA-associated kinetochores in HeLA cells during prometaphase. 
An enlarged region of interest (yellow square) shows a 200nm thin section 
through kinetochores. (B) A fraction of endogenous FANCA co-
immunoprecipitates with endogenous BUB1 in co-IP experiments in Hela cells. 
Whole cell lysate lane serves as input. 
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Figure 32. Confirmation of FANCA:BUB1 co-localization by 
immunofluorescence microscopy. Representative IF image using a different 
primary FANCA (blue) antibody (Ab5063) confirms FANCA co-localization with 
BUB1 (red) at kinetochores during prometaphase in HeLa cells. An enlarged 
region of interest (yellow squares) shows a 600nm thin section through 
kinetochores. 
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Figure 33. Phosphorylation of BUB1 substrates upon loss of FANCA 
remains unchanged. (A) Unchanged ratio of phospho-Cdc20S165 to total Cdc20 
was observed in FANCA-corrected compared to FANCA-/-. Cdc20 was 
immunoprecipitated from MNHN FANCA+ and FANCA-/- fibroblasts and 
immunoblotted with phospho-Cdc20S165. Cdc20, actin and Cdc27 were equal in 
whole cell lysates. (B) FANCA knockdown does not affect BUB1 kinase activity in 
Hela cells. BUB1 was immunoprecipitated from Hela cells transfected with 
control or FANCA siRNA. H2A was used as a BUB1-specific substrate and H1 
was used as a generic substrate to confirm that the assay was successful. No 
difference was observed in P32 H2A and P32 H1 in si-control versus si-FANCA 
transfected cells. (C) Western blot confirming successful knockdown of FANCA 
in HeLa cells. (D) BUB1 protein kinase activity is unchanged in FANCA+ and 
FANCA-/- MNHN fibroblasts. BUB1 was immunoprecipitated from MNHN 
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FANCA+ and FANCA-/- fibroblasts and H2A was used as a substrate. P32 H2A 
shows no difference between FANCA+ and FANCA-/- MNHN fibroblasts with 
equal levels of BUB1 and Actin in whole cell lysates. (E) pH2AT160, BUB1 target, 
is equally recruited to the prometaphase kinetochores. Representative images 
showing prometaphase FANCA+ (top panel) and FANCA-/- (bottom panel) 
MNHN fibroblasts stained with pH2AT160 (green) CENPA (red) antibodies.  
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Figure 34. Pattern of localization of FANCA during the cell cycle stages. 
FANCA localizes to HeLa CENPA-GFP marked kinetochores in prometaphase 
with decreasing kinetochore FANCA localization in late stages of mitosis. 
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Figure 35. Expression of FANCA protein is increased in early mitotic 
stages. (A) FANCA protein expression is increased as cells enter mitosis, when 
SAC is active, with a gradual decline as cells exit mitosis. CCNB1 serves as a 
mitotic marker. (B) Cell cycle dependent expression of FANCA is statistically 
significant. 
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Figure 36. Taxol and Nocodazole are drugs that modulate the microtubule. 
Schematic depicting microtubule status in cells treated with nocadazole or taxol. 
Nocodazole causes microtubule disassembly in addition to lack of kinetochore 
attachment and tension while taxol results in microtubule stabilization and lack of 
kinetochore tension. 
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Figure 37. Pattern of FANCA localization in nocodazole vs taxol treated 
cells. Inter-centromeric localization of FANCA in nocodazole arrested HeLa cells 
compared to kinetochore co-localization of FANCA with BUB1 in taxol-arrested 
cells. 
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Figure 38. FANCA interacts with SAC protein kinase, BUB1, in a cell cycle 
and microtubule-dependent manner. (A) Representative schematic 
demonstrating inter-centromeric location of FANCA in the absence of 
microtubules in nocodazole-treated cells and a corresponding quantification of 
this localization. (B) Fluorescence intensity line profiles indicate that FANCA co-
localizes with Aurora B in nocodazole and not in taxol-treated cells. 
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 At least 300 kinetochores per cell line were counted. ****P < 0.0001 Fisher’s 
exact test. 
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Figure 39. Inter-centromeric localization of BUB1 with Aurora Kinase B 
(AURKB) following treatment with Nocadozole. (A) Immunofluorescence 
images showing FANCA co-localizing with AURKB between two kinetochores 
(intercentromeric) in the presence of nocodazole, but not taxol. (B) Schematic 
(upper panel) depicting the FANCA:AURKB co-localization, which is significantly 
increased in nocodazole-treated cells when compared with taxol-treated cells 
upon quantification of this interaction on kinetochores. ****P < 0.0001 Fisher’s 
exact test. 
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Figure 40. FANCA interaction with BUB1 in the presence of microtubule-
altering agents. Increased FANCA:BUB1 interaction in the presence of taxol 
when compared to nocodazole treated Hela cells co-immunoprecipitated with 
FANCA and blotted for BUB1. No change is noted in FANCA and BUB1 protein 
expression in whole cell lysates. 
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FANCA regulates PCAF dependent BUBR1 acetylation promoting BUBR1 
stability 
Next, we pursued the hypothesis that loss of FANCA affects BUBR1 mitotic 
functions. BUBR1 localizes to the kinetochore and interacts with CDC20, MAD2 
and BUB3 to form the mitotic checkpoint complex (MCC), which sequesters 
CDC20 from anaphase promoting complex (APC/C)  to prevent anaphase 
transition until SAC is satisfied (V. Sudakin et al., 2001). We asked whether 
faster anaphase onset and subsequent mitotic exit observed upon loss of 
FANCA (Figure 25, (Nalepa et al., 2013)) could be attributed to dysregulated 
BUBR1 signaling, especially since FANCA and BUBR1 were found to interact in 
the context of SAC activation (Figure 41). Indeed, BUBR1 protein levels are 
decreased in FANCA-/- cells in mitosis (Figure 42A) in a proteasome dependent 
manner (Figure 42B). This suggests faster BUBR1 degradation in FANCA-/- 
cells, which was confirmed by inhibition of de-novo protein synthesis upon 
cycloheximide treatment (Figure 42C-43). Given these findings, we addressed 
what the mechanism for accelerated BUBR1 degradation upon loss of FANCA 
might be. 
 
Acetylation of BUBR1 at lysine residue K250 is important for its stability in 
prometaphase thus maintaining APC/Cdc20 inhibition until proper chromosome-
spindle attachment is achieved (I. Park et al., 2013). We reasoned that 
dysregulated BUBR1 acetylation may explain decreased BUBR1 stability upon 
loss of FANCA. Indeed, experiments using published and validated antibody 
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recognizing acetylated lysine K250 residue on BUBR1 consistently showed 
diminished BUBR1Ac-K250 kinetochore localization in FANCA-deficient patient 
fibroblasts (Figure 44A). Concomitantly, BUBR1Ac-K250 protein expression was 
found to be decreased in two FANCA-/- patient fibroblast cell lines (Figure 44B, 
Figure 45A) and in HeLa cells transfected with FANCA siRNA (Figure 45B). 
Collectively, this shows that dysregulated BUBR1 acetylation contributes to 
decreased BUBR1 stability in FANCA-/- cells. 
 
Choi et al also reported that BRCA2 (also known as FANCD1), a downstream 
effector of the FA pathway, is essential in recruiting PCAF acetyl transferase to 
kinetochores for BUBR1 acetylation (Choi et al., 2009). Our observation of 
decreased acetylated BUBR1 upon loss of FANCA prompted us to interrogate 
the PCAF- FANCD1 signaling chain during prometaphase. Indeed, 
immunofluorescence revealed that PCAF-positive kinetochores were diminished 
upon loss of FANCA in patient fibroblasts and in si-FANCA transfected Hela cells 
(Figure 46-47). We also demonstrate decreased BRCA2/FANCD1 recruitment to 
kinetochores in FANCA-deficient patient fibroblasts and in si-FANCA transfected 
Hela cells (Figure 48-49). Collectively, these results support a model in which 
FANCA is required for recruitment of FANCD1 and PCAF to kinetochores which 
acetylates and stabilizes BUBR1 allowing for error free chromosome segregation 
(Figure 50).  
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Figure 41. FANCA interacts with BUBR1. A fraction of endogenous FANCA co-
immunoprecipitates with BUBR1 in co-IP experiments in HeLa cells treated with 
or without nocodazole or taxol. CCNB1 serves as a mitotic control and actin as a 
loading control.  
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Figure 42. Decreased BUBR1 stability upon loss of FANCA. (A) Decreased 
BUBR1 and CCNB1 levels are observed in FANCA-/- JRAST fibroblasts 
compared to FANCA+ cells following 30-minute release from RO-3306 induced 
G2 arrest. No significant difference in BUBR1 and CCNB1 is observed in 
unsynchronized FANCA+ and FANCA-/- JRAST fibroblasts with equal protein 
loading indicated by Actin. (B) Western blot showing restored BUBR1 expression 
in FANCA-/- cells following 3-hour release from RO-3306 induced G2 arrest into 
MG132, a proteasome inhibitor. (C) Faster BUBR1 protein degradation is 
observed in FANCA-/- JRAST fibroblasts following 120-minute treatment with 
20ug/ml cyclohexamide (CHX) when compared to FANCA+ counterparts 
following the same treatment. No difference in BUBR1 degradation is observed 
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at baseline (0 seconds). Actin serves as a loading control while CCNB1 serves 
as a mitotic marker.   
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Figure 43. FANCA-/- cells exhibit faster BUBR1 degradation. (A) Western blot 
showing decreased BUBR1 protein levels in FANCA-/- JRAST cells (right) 
following 120-minute treatment with 20 µg/ml cyclohexamide (CHX) when 
compared to CHX treated FANCA+ fibroblasts (left). Actin serves as a loading 
control. (B) BUBR1 levels in CHX treated cells were normalized to untreated 
cells. Quantification of normalized BUBR1 expression shows increased BUBR1 
degradation in FANCA-/- cells. *P < 0.05. two-sided student’s t-test. Six different 
replicates were quantified (data not shown).    
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Figure 44. FANCA is essential for BRCA2 mediated BUBR1 acetylation. (A) 
Immunofluorescence microscopy demonstrates decreased Ac-BUBR1 
localization to kinetochores (left) in FANCA-deficient MNHN fibroblasts in 
comparison to FANCA corrected cells. Quantification shows significantly 
decreased BUBr1AcK250 positive kinetochores in FANCA-/- cells compared to 
FANCA+. (B) Unsynchronized FANCA -/- JRAST fibroblasts exhibit decreased 
acetylated BUBR1 expression when compared to FANCA+ counterparts without 
a difference in CCNB1 or alpha-tubulin expression.   
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Figure 45. Levels of acetylated BUBR1 protein is decreased upon loss of 
FANCA in unsynchronized cells. (A) Decreased expression of acetylated-
BUBR1 and quantification of BUBR1AcK250/BUBR1 ratio in unsynchronized 
FANCA -/- MNHN fibroblasts when compared to FANCA+ counterparts. 
Quantification of BUBR1AcK250/BUBR1 ratio is shown on the right. No difference 
in CDC27 is noted among both cell lines suggesting equal mitotic cellular index. 
(B) FANCA siRNA transfected Hela cells exhibit decreased 
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BUBR1AcK250/BUBR1 expression compared to control siRNA with equal 
CCBN1 expression.  
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Figure 46. Diminished localization of PCAF in FANCA-/- MNHN fibroblast 
kinetochores. (A) Representative microscopy images depicting decreased 
PCAF (red) positive CENPA (green) kinetochores in FANCA-/- MNHN (upper 
panel) fibroblasts compared to FANCA+ MNHN fibroblasts (lower panel). (B) 
Quantification of at least 300 kinetochores demonstrates a statistically significant 
decrease in PCAF positive kinetochores in FANCA-/- fibroblasts compared to 
FANCA+ counterparts. ****P < 0.0001 Fisher’s exact test. 
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Figure 47. PCAF recruitment is reduced upon loss of FANCA. (A) Diminished 
PCAF (red) positive CENPA (green) kinetochores in FANCA siRNA transfected 
HeLa cells (upper panel) compared to control siRNA transfected HeLa cells 
(lower panel). (B) At least 300 kinetochores were used to quantify PCAF positive 
kinetochores, which shows a statistically significant decrease in PCAF 
recruitment in FANCA siRNA compared to control siRNA transfected HeLa cells. 
****P < 0.0001 Fisher’s exact test. 
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Figure 48. Diminished localization of FANCD1 in FANCA-/- MNHN fibroblast 
kinetochores. (A) Representative microscopy images depicting decreased 
FANCD1 (red) positive CENPA (green) kinetochores in FANCA-/- MNHN (upper 
panel) fibroblasts compared to FANCA+ MNHN fibroblasts (lower panel). (B) 
Quantification of at least 300 kinetochores demonstrates a statistically significant 
decrease in FANCD1 positive kinetochores in FANCA-/- fibroblasts compared to 
FANCA+ counterparts. ****P < 0.0001 Fisher’s exact test. 
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Figure 49. Diminished FANCD1 localization is observed upon knockdown 
of FANCA. (A) Diminished FANCD1 (red) positive CENPA (green) kinetochores 
in FANCA siRNA transfected HeLa cells (upper panel) compared to control 
siRNA transfected HeLa cells (lower panel). (B) At least 300 kinetochores were 
used to quantify FANCD1 positive kinetochores, which shows a statistically 
significant decrease in FANCD1 recruitment in FANCA siRNA compared to 
control siRNA transfected HeLa cells. ****P<0.0001 student T-test 
  
132 
 
Figure 50. FANCA maintains the SAC through a mechanism involving 
acetylation of BUBR1 protein. Schematic showing the proposed mechanism for 
crosstalk between the SAC and FA pathway. FANCA is required for FANCD1 
recruitment of PCAF to kinetochore and its acetylation of BUBR1, which ensures 
active SAC checkpoint error free chromosome segregation and genomic stability.   
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Discussion 
Our study uses an unbiased shRNA kinome screen that identified several 
kinases, including SAC kinases named BUB1 and BUBR1, to be synthetically 
lethal with loss of FANCA. We provide the first line of evidence that showcases 
FANCA’s role in ensuring a robust SAC by participating in the 
FANCD1:PCAF:BUBR1 acetylation cascade. Furthermore, revealing that FANCA 
regulates SAC through BUBR1 acetylation provides an explanation for BUB1 
synthetic lethality in FANCA-/- cells. Indeed, losing FANCA and subsequently 
compromising BUBR1 inhibition of Cdc20 results in weakened SAC, but losing 
BUB1 as well may result in complete abrogation of the SAC and consequently 
cell death. Collectively, this study provides a mechanistic insight into the 
signaling pathways through which FANCA may exert its mitotic control. The 
synthetic lethality of BUB1 and BUBR1 provides therapeutic platform for targeting 
the SAC in FANCA-/- cells, which could prove to be an effective strategy for 
selective killing of FANCA-deficient cancers in Fanconi Anemia patients, in 
addition to, the general population.  
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CHAPTER FIVE 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Our understanding of the functions of the FA pathway in mitosis is only starting to 
take shape. In this study, we showed that genomic instability in FA arises from a 
combination of interphase DNA damage and mitotic aberrations. We also 
demonstrated that FANCA localizes to the prometaphase kinetochore to regulate 
the SAC through controlling BUBR1 acetylation. Our published and unpublished 
data suggest that FA proteins localize to the centrosome and are essential for 
centrosome maintenance (Kim et al., 2013; Nalepa et al., 2013; Zou et al., 2013; 
Zou et al., 2014).  Still, many questions regarding the roles of FA proteins in 
mitosis remain unanswered. Future studies will focus the mechanism through 
which FANCA exerts its function in centrosome maintenance and spindle 
nucleation. It would be also interesting to understand how FANCA is targeted to 
the kinetochore and spindle.  
 
Furthermore, our kinome-wide shRNA screen identified a number of candidate 
kinases whose silencing selectively impacts survival of FANCA-/- cells. Here we 
evaluated the mechanistic connection between FANCA and BUBR1 axis, but we 
are planning to systematically evaluate other candidates in our future studies as 
other kinases may also provide significant insights into FANCA-dependent 
mechanisms of cell division. In these studies, we will prioritize candidates that 
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can be effectively targeted with small-molecule chemotherapeutics as this would 
facilitate pre-clinical evaluation of the most promising candidates.   
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